ACR Meeting Abstracts

ACR Meeting Abstracts

Session » ACR Convergence 2025

9:45AM-10:00AM
Abstract Number: 0772
Redefining When to Biopsy the Kidney in Patients with SLE
10:00AM-10:15AM
Abstract Number: 0773
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
10:15AM-10:30AM
Abstract Number: 0774
Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
10:30AM-12:30PM
Abstract Number: 0317
“No matter how great my doctor is, he hasn’t had a knee replacement, he doesn’t understand all that pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement
10:30AM-12:30PM
Abstract Number: 0189
“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists
10:30AM-12:30PM
Abstract Number: 0359
“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
10:30AM-12:30PM
Abstract Number: 0446
A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0613
A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
10:30AM-12:30PM
Abstract Number: 0719
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
10:30AM-12:30PM
Abstract Number: 0309
A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
10:30AM-12:30PM
Abstract Number: 0041
A genetically determined, serine-based and phosphorylation-dependent molecular switch regulates the inflammatory potential of human IgA
10:30AM-12:30PM
Abstract Number: 0182
A Joint Effort: Implementing Depression Screening in a Safety-Net Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 0467
A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
10:30AM-12:30PM
Abstract Number: 0519
A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study
10:30AM-12:30PM
Abstract Number: 0263
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
10:30AM-12:30PM
Abstract Number: 0221
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
10:30AM-12:30PM
Abstract Number: 0029
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
10:30AM-12:30PM
Abstract Number: 0277
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
10:30AM-12:30PM
Abstract Number: 0473
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
10:30AM-12:30PM
Abstract Number: 0303
A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 0037
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
10:30AM-12:30PM
Abstract Number: 0231
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
10:30AM-12:30PM
Abstract Number: 0692
A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
10:30AM-12:30PM
Abstract Number: 0114
A rare variant in the Extl3 gene is associated with altered Wnt signaling pathway in a novel mouse model of axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0735
A Real-World Study from the Greater Paris Clinical Data Warehouse
10:30AM-12:30PM
Abstract Number: 0699
A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0698
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
10:30AM-12:30PM
Abstract Number: 0209
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
10:30AM-12:30PM
Abstract Number: 0510
A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease
10:30AM-12:30PM
Abstract Number: 0388
A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0275
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
10:30AM-12:30PM
Abstract Number: 0646
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
10:30AM-12:30PM
Abstract Number: 0636
AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways
10:30AM-12:30PM
Abstract Number: 0097
Aberrant histone marks increase the inflammatory phenotype of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) by suppressing NUB1 induction
10:30AM-12:30PM
Abstract Number: 0645
Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
10:30AM-12:30PM
Abstract Number: 0291
Acute onset inflammatory myositis: Clinical features and survival.
10:30AM-12:30PM
Abstract Number: 0191
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
10:30AM-12:30PM
Abstract Number: 0744
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
10:30AM-12:30PM
Abstract Number: 0607
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
10:30AM-12:30PM
Abstract Number: 0296
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
10:30AM-12:30PM
Abstract Number: 0148
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
10:30AM-12:30PM
Abstract Number: 0680
Altered miRNA patterns of peripheral blood mononuclear cells show correlations with pulmonary manifestations of systemic sclerosis
10:30AM-12:30PM
Abstract Number: 0356
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
10:30AM-12:30PM
Abstract Number: 0230
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
10:30AM-12:30PM
Abstract Number: 0592
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
10:30AM-12:30PM
Abstract Number: 0591
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
10:30AM-12:30PM
Abstract Number: 0389
An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0376
An Internet-Delivered, Arthritis-Tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-Morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-Users
10:30AM-12:30PM
Abstract Number: 0471
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
10:30AM-12:30PM
Abstract Number: 0129
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
10:30AM-12:30PM
Abstract Number: 0711
Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
10:30AM-12:30PM
Abstract Number: 0729
ANCA-associated vasculitis – does the type matter?
10:30AM-12:30PM
Abstract Number: 0086
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
10:30AM-12:30PM
Abstract Number: 0286
Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients
10:30AM-12:30PM
Abstract Number: 0647
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: an open-label pilot study
10:30AM-12:30PM
Abstract Number: 0281
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 0529
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0076
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0631
Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.
10:30AM-12:30PM
Abstract Number: 0528
Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes In Early Treatment Naïve Psoriatic Arthritis and Correlate With 1-year Disease Activity
10:30AM-12:30PM
Abstract Number: 0109
Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
10:30AM-12:30PM
Abstract Number: 0117
Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?
10:30AM-12:30PM
Abstract Number: 0308
Artificial Intelligence Assisted Extraction of Patient-Reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
10:30AM-12:30PM
Abstract Number: 0177
Artificial intelligence in adult and paediatric rheumatology practice and research: pilot results from an international survey
10:30AM-12:30PM
Abstract Number: 0548
Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
10:30AM-12:30PM
Abstract Number: 0569
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
10:30AM-12:30PM
Abstract Number: 0374
Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
10:30AM-12:30PM
Abstract Number: 0360
Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
10:30AM-12:30PM
Abstract Number: 0363
Assessing Whole Health Needs in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0279
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
10:30AM-12:30PM
Abstract Number: 0455
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0604
Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0516
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
10:30AM-12:30PM
Abstract Number: 0758
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0395
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
10:30AM-12:30PM
Abstract Number: 0345
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
10:30AM-12:30PM
Abstract Number: 0146
Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
10:30AM-12:30PM
Abstract Number: 0387
Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health
10:30AM-12:30PM
Abstract Number: 0158
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
10:30AM-12:30PM
Abstract Number: 0443
Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0173
Association Between the Ratio of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and All-Cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
10:30AM-12:30PM
Abstract Number: 0673
Association Between Vasoactive-Vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence From a EUSTAR Study
10:30AM-12:30PM
Abstract Number: 0708
Association Of Choroidal Sub-foveal Thickness With Skin Manifestations And Serum Monocyte HDL Ratio In Patients With Systemic Sclerosis-A Case Control Study
10:30AM-12:30PM
Abstract Number: 0691
Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0046
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 0375
Association of Glucocorticoid Toxicity Index Scores with Quality-of-Life and Healthcare Resource Utilization at 6 Months in a Real-World Cohort of Individuals Receiving Glucocorticoids
10:30AM-12:30PM
Abstract Number: 0634
Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
10:30AM-12:30PM
Abstract Number: 0079
Association of Protein Arginine Deiminase 4 with the Myosin-9 Motor Complex
10:30AM-12:30PM
Abstract Number: 0491
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
10:30AM-12:30PM
Abstract Number: 0602
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
10:30AM-12:30PM
Abstract Number: 0340
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
10:30AM-12:30PM
Abstract Number: 0477
At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
10:30AM-12:30PM
Abstract Number: 0001
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 0617
Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
10:30AM-12:30PM
Abstract Number: 0250
Autoinflammatory diseases in adult patients. Spanish registry.
10:30AM-12:30PM
Abstract Number: 0323
Automated Effusion-Synovitis Volume is Prognostic and Responsive to Knee Osteoarthritis Progression: Data from the Osteoarthritis Initiative
10:30AM-12:30PM
Abstract Number: 0583
Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
10:30AM-12:30PM
Abstract Number: 0240
Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
10:30AM-12:30PM
Abstract Number: 0649
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
10:30AM-12:30PM
Abstract Number: 0642
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
10:30AM-12:30PM
Abstract Number: 0442
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
10:30AM-12:30PM
Abstract Number: PP07
Beyond the Medication: Creating a Toolbox of Complementary Therapies
10:30AM-12:30PM
Abstract Number: 0136
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
10:30AM-12:30PM
Abstract Number: 0324
Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium
10:30AM-12:30PM
Abstract Number: 0574
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
10:30AM-12:30PM
Abstract Number: 0024
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
10:30AM-12:30PM
Abstract Number: 0212
Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0732
Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
10:30AM-12:30PM
Abstract Number: 0655
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
10:30AM-12:30PM
Abstract Number: 0337
Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
10:30AM-12:30PM
Abstract Number: 0228
Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
10:30AM-12:30PM
Abstract Number: 0020
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
10:30AM-12:30PM
Abstract Number: 0431
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0536
Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
10:30AM-12:30PM
Abstract Number: 0172
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
10:30AM-12:30PM
Abstract Number: 0252
Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH
10:30AM-12:30PM
Abstract Number: 0015
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
10:30AM-12:30PM
Abstract Number: 0116
Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI
10:30AM-12:30PM
Abstract Number: 0733
Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0496
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
10:30AM-12:30PM
Abstract Number: 0355
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
10:30AM-12:30PM
Abstract Number: 0579
Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
10:30AM-12:30PM
Abstract Number: 0741
Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0752
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
10:30AM-12:30PM
Abstract Number: 0470
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
10:30AM-12:30PM
Abstract Number: 0008
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
10:30AM-12:30PM
Abstract Number: 0629
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
10:30AM-12:30PM
Abstract Number: 0441
Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA
10:30AM-12:30PM
Abstract Number: 0266
Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0717
Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 0078
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0278
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
10:30AM-12:30PM
Abstract Number: 0255
Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis
10:30AM-12:30PM
Abstract Number: 0550
Clinical and Genetic Factors Associated with Anti-TNF Therapy Initiation in Radiographic Axial Spondyloarthritis: A 15-Year Observational Study
10:30AM-12:30PM
Abstract Number: 0669
Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
10:30AM-12:30PM
Abstract Number: 0248
Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort
10:30AM-12:30PM
Abstract Number: 0035
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
10:30AM-12:30PM
Abstract Number: 0365
Clinical Characteristics and Psychosocial Outcomes of Patients with UCTD Compared to SLE
10:30AM-12:30PM
Abstract Number: 0392
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
10:30AM-12:30PM
Abstract Number: 0269
Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group
10:30AM-12:30PM
Abstract Number: 0282
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
10:30AM-12:30PM
Abstract Number: 0422
Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0271
Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
10:30AM-12:30PM
Abstract Number: 0294
Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
10:30AM-12:30PM
Abstract Number: 0162
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
10:30AM-12:30PM
Abstract Number: 0670
Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
10:30AM-12:30PM
Abstract Number: 0091
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities
10:30AM-12:30PM
Abstract Number: 0623
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
10:30AM-12:30PM
Abstract Number: PP06
Co-Creation of Exercise Videos by Patients and Professionals to Support Patient Empowerment
10:30AM-12:30PM
Abstract Number: 0565
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
10:30AM-12:30PM
Abstract Number: 0103
Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0484
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
10:30AM-12:30PM
Abstract Number: 0254
Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis
10:30AM-12:30PM
Abstract Number: 0435
Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0632
Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0406
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0589
Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
10:30AM-12:30PM
Abstract Number: 0535
Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
10:30AM-12:30PM
Abstract Number: 0342
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
10:30AM-12:30PM
Abstract Number: 0290
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
10:30AM-12:30PM
Abstract Number: 0635
Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0352
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
10:30AM-12:30PM
Abstract Number: 0287
Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 0028
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
10:30AM-12:30PM
Abstract Number: 0304
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
10:30AM-12:30PM
Abstract Number: 0083
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0449
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
10:30AM-12:30PM
Abstract Number: 0027
Consistent Method to Generate Hyaline Cartilage from Human Induced Pluripotent Stem Cell-Derived Multi-Tissue Organoids
10:30AM-12:30PM
Abstract Number: 0242
Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
10:30AM-12:30PM
Abstract Number: 0357
Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)
10:30AM-12:30PM
Abstract Number: 0348
Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 0525
Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
10:30AM-12:30PM
Abstract Number: 0218
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
10:30AM-12:30PM
Abstract Number: 0315
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
10:30AM-12:30PM
Abstract Number: 0208
Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
10:30AM-12:30PM
Abstract Number: 0720
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
10:30AM-12:30PM
Abstract Number: 0141
Cytokine profiles in antiphospholipid syndrome
10:30AM-12:30PM
Abstract Number: 0307
Cytokine Profiling of Molecular Endotypes of Knee Osteoarthritis: Insights from the IMI-APPROACH cohort
10:30AM-12:30PM
Abstract Number: 0128
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
10:30AM-12:30PM
Abstract Number: 0285
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0366
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
10:30AM-12:30PM
Abstract Number: 0518
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
10:30AM-12:30PM
Abstract Number: 0547
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0672
Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
10:30AM-12:30PM
Abstract Number: 0472
Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
10:30AM-12:30PM
Abstract Number: 0372
Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0033
Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
10:30AM-12:30PM
Abstract Number: 0176
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
10:30AM-12:30PM
Abstract Number: 0260
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
10:30AM-12:30PM
Abstract Number: 0018
Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
10:30AM-12:30PM
Abstract Number: 0213
Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
10:30AM-12:30PM
Abstract Number: 0689
Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
10:30AM-12:30PM
Abstract Number: 0538
Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
10:30AM-12:30PM
Abstract Number: 0217
Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
10:30AM-12:30PM
Abstract Number: 0630
Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0270
Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
10:30AM-12:30PM
Abstract Number: 0507
Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren’s disease of recent onset versus sicca controls.
10:30AM-12:30PM
Abstract Number: 0333
Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
10:30AM-12:30PM
Abstract Number: 0334
Diagnostic Test Accuracy of Ultrasound for Detecting Knee Osteoarthritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0763
Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
10:30AM-12:30PM
Abstract Number: 0060
Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121
10:30AM-12:30PM
Abstract Number: 0133
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
10:30AM-12:30PM
Abstract Number: 0367
Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0358
Different Perspectives between Physicians and Patients on Treatment Priorities and Challenges in Still’s Disease
10:30AM-12:30PM
Abstract Number: 0233
Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 0713
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
10:30AM-12:30PM
Abstract Number: 0584
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
10:30AM-12:30PM
Abstract Number: 0633
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis
10:30AM-12:30PM
Abstract Number: 0179
Digital Divide in Rheumatology: Patterns of Technology and AI Adoption Across Generations of Specialists
10:30AM-12:30PM
Abstract Number: 0192
Digital Empowerment on Hold: Adoption Gaps in Prescribable Digital Health Applications – A National Cross-Sectional Study from Germany
10:30AM-12:30PM
Abstract Number: 0180
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
10:30AM-12:30PM
Abstract Number: 0306
Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
10:30AM-12:30PM
Abstract Number: 0335
Discontinuation and Non-Publication of Osteoarthritis Clinical Studies: A Cross-Sectional Analysis of 10,686,413 Patients
10:30AM-12:30PM
Abstract Number: 0409
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0013
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
10:30AM-12:30PM
Abstract Number: 0506
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
10:30AM-12:30PM
Abstract Number: 0404
Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
10:30AM-12:30PM
Abstract Number: 0104
Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0700
Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
10:30AM-12:30PM
Abstract Number: 0687
Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
10:30AM-12:30PM
Abstract Number: 0759
Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
10:30AM-12:30PM
Abstract Number: 0094
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
10:30AM-12:30PM
Abstract Number: 0637
DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
10:30AM-12:30PM
Abstract Number: 0625
DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
10:30AM-12:30PM
Abstract Number: 0044
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
10:30AM-12:30PM
Abstract Number: 0038
DNA Methylation Signatures of Smoking in Labial Salivary Gland Tissue in a Sjögren’s Disease Cohort
10:30AM-12:30PM
Abstract Number: 0379
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
10:30AM-12:30PM
Abstract Number: 0021
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
10:30AM-12:30PM
Abstract Number: 0336
Does Baseline Physical Function Moderate Change in Steps/day Following a Telephone-Delivered Walk With Ease Program?
10:30AM-12:30PM
Abstract Number: 0462
Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
10:30AM-12:30PM
Abstract Number: 0748
Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
10:30AM-12:30PM
Abstract Number: 0475
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
10:30AM-12:30PM
Abstract Number: 0362
Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry
10:30AM-12:30PM
Abstract Number: 0497
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
10:30AM-12:30PM
Abstract Number: 0568
Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
10:30AM-12:30PM
Abstract Number: 0512
Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 0144
Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
10:30AM-12:30PM
Abstract Number: 0115
Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
10:30AM-12:30PM
Abstract Number: 0488
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
10:30AM-12:30PM
Abstract Number: 0558
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
10:30AM-12:30PM
Abstract Number: 0155
Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
10:30AM-12:30PM
Abstract Number: 0166
Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
10:30AM-12:30PM
Abstract Number: 0063
Effect of alpha-ketoglutarate on Synovial Fibroblasts-Mediated Inflammation in Arthritis
10:30AM-12:30PM
Abstract Number: 0590
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 0596
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
10:30AM-12:30PM
Abstract Number: 0095
Effect of JAK Inhibitors on Osteoblast Differentiation
10:30AM-12:30PM
Abstract Number: 0149
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0244
Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
10:30AM-12:30PM
Abstract Number: 0495
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
10:30AM-12:30PM
Abstract Number: 0737
Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review
10:30AM-12:30PM
Abstract Number: 0702
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
10:30AM-12:30PM
Abstract Number: 0736
Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
10:30AM-12:30PM
Abstract Number: 0273
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
10:30AM-12:30PM
Abstract Number: 0581
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
10:30AM-12:30PM
Abstract Number: 0712
Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 0660
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
10:30AM-12:30PM
Abstract Number: 0393
Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0573
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
10:30AM-12:30PM
Abstract Number: 0766
Effects of Walking During the 6-Minute Walk Test on Cognition in Adults with Knee Replacement
10:30AM-12:30PM
Abstract Number: 0662
Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
10:30AM-12:30PM
Abstract Number: 0563
Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
10:30AM-12:30PM
Abstract Number: 0241
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
10:30AM-12:30PM
Abstract Number: 0480
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
10:30AM-12:30PM
Abstract Number: 0312
Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0489
Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0487
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
10:30AM-12:30PM
Abstract Number: 0599
Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0398
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
10:30AM-12:30PM
Abstract Number: 0557
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
10:30AM-12:30PM
Abstract Number: 0676
Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
10:30AM-12:30PM
Abstract Number: 0049
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
10:30AM-12:30PM
Abstract Number: 0101
Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0551
Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
10:30AM-12:30PM
Abstract Number: 0243
Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
10:30AM-12:30PM
Abstract Number: 0722
Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
10:30AM-12:30PM
Abstract Number: 0310
Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
10:30AM-12:30PM
Abstract Number: 0138
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
10:30AM-12:30PM
Abstract Number: 0614
Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
10:30AM-12:30PM
Abstract Number: 0530
Evaluating ChatGPT’s Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
10:30AM-12:30PM
Abstract Number: 0339
Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass
10:30AM-12:30PM
Abstract Number: 0469
Evaluating Large Language Models for Automated Joint Involvement Analysis in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0222
Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
10:30AM-12:30PM
Abstract Number: 0531
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
10:30AM-12:30PM
Abstract Number: 0556
Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0194
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
10:30AM-12:30PM
Abstract Number: 0418
Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0193
Evaluation of electronic health record and efficiency tool utilization by pediatric subspecialists
10:30AM-12:30PM
Abstract Number: 0626
Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
10:30AM-12:30PM
Abstract Number: 0216
Evaluation of oral treatment adherence in Systemic Lupus Erythematosus patients: indentification of risks profiles
10:30AM-12:30PM
Abstract Number: 0681
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0652
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
10:30AM-12:30PM
Abstract Number: 0025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
10:30AM-12:30PM
Abstract Number: 0089
Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0351
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
10:30AM-12:30PM
Abstract Number: 0701
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
10:30AM-12:30PM
Abstract Number: 0152
Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)
10:30AM-12:30PM
Abstract Number: 0300
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
10:30AM-12:30PM
Abstract Number: 0742
Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
10:30AM-12:30PM
Abstract Number: 0438
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0065
Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
10:30AM-12:30PM
Abstract Number: 0399
External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0714
Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort
10:30AM-12:30PM
Abstract Number: 0368
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
10:30AM-12:30PM
Abstract Number: 0576
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
10:30AM-12:30PM
Abstract Number: 0761
Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0750
Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
10:30AM-12:30PM
Abstract Number: 0346
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
10:30AM-12:30PM
Abstract Number: 0447
Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
10:30AM-12:30PM
Abstract Number: 0059
Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
10:30AM-12:30PM
Abstract Number: 0246
Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
10:30AM-12:30PM
Abstract Number: 0338
Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0432
Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0764
Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
10:30AM-12:30PM
Abstract Number: 0305
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
10:30AM-12:30PM
Abstract Number: 0509
Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
10:30AM-12:30PM
Abstract Number: 0585
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
10:30AM-12:30PM
Abstract Number: 0527
Gaps In Documentation Of Psoriatic Arthritis Domains In General Rheumatologic Practices Compared To Rheumatology-Dermatology Combined Clinics
10:30AM-12:30PM
Abstract Number: 0326
Gender Disparities in Clinical Outcomes Among Older Adults with Knee Osteoarthritis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0532
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
10:30AM-12:30PM
Abstract Number: 0174
Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0045
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
10:30AM-12:30PM
Abstract Number: 0593
Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0022
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
10:30AM-12:30PM
Abstract Number: 0167
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
10:30AM-12:30PM
Abstract Number: 0743
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
10:30AM-12:30PM
Abstract Number: 0695
Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction
10:30AM-12:30PM
Abstract Number: 0445
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0319
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0734
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
10:30AM-12:30PM
Abstract Number: 0284
Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
10:30AM-12:30PM
Abstract Number: 0668
Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0096
GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
10:30AM-12:30PM
Abstract Number: 0354
Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
10:30AM-12:30PM
Abstract Number: 0364
Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
10:30AM-12:30PM
Abstract Number: 0517
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
10:30AM-12:30PM
Abstract Number: 0190
Health literacy and comorbidity burden: a cluster analysis in a national cohort of people with inflammatory arthritis
10:30AM-12:30PM
Abstract Number: 0156
Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
10:30AM-12:30PM
Abstract Number: 0039
Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome
10:30AM-12:30PM
Abstract Number: 0383
Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 0425
High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease
10:30AM-12:30PM
Abstract Number: 0549
High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study
10:30AM-12:30PM
Abstract Number: 0328
High synovial fluid leukocyte counts and markers of TLR activation correlate with poorer response to injections in patients with knee OA
10:30AM-12:30PM
Abstract Number: 0143
High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome
10:30AM-12:30PM
Abstract Number: 0727
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
10:30AM-12:30PM
Abstract Number: 0384
Hip Fracture Hospitalization Trends in Osteoporotic Patients (2016–2022): National Data Insights
10:30AM-12:30PM
Abstract Number: 0537
HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
10:30AM-12:30PM
Abstract Number: 0073
HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0659
Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
10:30AM-12:30PM
Abstract Number: 0704
Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
10:30AM-12:30PM
Abstract Number: 0232
Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience
10:30AM-12:30PM
Abstract Number: 0082
IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
10:30AM-12:30PM
Abstract Number: 0562
Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
10:30AM-12:30PM
Abstract Number: 0040
Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
10:30AM-12:30PM
Abstract Number: 0067
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 0526
Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 0378
Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis
10:30AM-12:30PM
Abstract Number: 0347
Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
10:30AM-12:30PM
Abstract Number: 0061
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
10:30AM-12:30PM
Abstract Number: 0403
IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
10:30AM-12:30PM
Abstract Number: 0088
Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0586
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
10:30AM-12:30PM
Abstract Number: 0030
Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study
10:30AM-12:30PM
Abstract Number: 0204
Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
10:30AM-12:30PM
Abstract Number: 0696
Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0072
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
10:30AM-12:30PM
Abstract Number: 0640
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
10:30AM-12:30PM
Abstract Number: 0476
Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
10:30AM-12:30PM
Abstract Number: 0075
Impact of CXCL2 and IL-11 from Rheumatoid Arthritis Synovial Fibroblasts on Angiogenesis and Endothelial Cell Network Formation
10:30AM-12:30PM
Abstract Number: 0746
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
10:30AM-12:30PM
Abstract Number: 0215
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
10:30AM-12:30PM
Abstract Number: 0343
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
10:30AM-12:30PM
Abstract Number: 0251
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
10:30AM-12:30PM
Abstract Number: 0503
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
10:30AM-12:30PM
Abstract Number: 0456
Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.
10:30AM-12:30PM
Abstract Number: 0559
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
10:30AM-12:30PM
Abstract Number: 0751
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0693
Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
10:30AM-12:30PM
Abstract Number: 0417
Implementation of a Communication Aid in Juvenile Idiopathic Arthritis Patient Visits, a Quality Improvement Study
10:30AM-12:30PM
Abstract Number: 0373
Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
10:30AM-12:30PM
Abstract Number: 0520
Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
10:30AM-12:30PM
Abstract Number: 0205
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
10:30AM-12:30PM
Abstract Number: 0448
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
10:30AM-12:30PM
Abstract Number: 0408
Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0644
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
10:30AM-12:30PM
Abstract Number: 0564
Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
10:30AM-12:30PM
Abstract Number: 0413
Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative
10:30AM-12:30PM
Abstract Number: 0224
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
10:30AM-12:30PM
Abstract Number: 0410
Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program
10:30AM-12:30PM
Abstract Number: 0381
Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
10:30AM-12:30PM
Abstract Number: 0210
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
10:30AM-12:30PM
Abstract Number: 0653
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
10:30AM-12:30PM
Abstract Number: 0108
In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0003
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
10:30AM-12:30PM
Abstract Number: 0433
In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
10:30AM-12:30PM
Abstract Number: 0728
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
10:30AM-12:30PM
Abstract Number: 0154
Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
10:30AM-12:30PM
Abstract Number: 0353
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
10:30AM-12:30PM
Abstract Number: 0753
Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0718
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
10:30AM-10:45AM
Abstract Number: 0775
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
10:30AM-12:30PM
Abstract Number: 0219
Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures
10:30AM-12:30PM
Abstract Number: 0132
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
10:30AM-12:30PM
Abstract Number: 0769
Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 0677
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
10:30AM-12:30PM
Abstract Number: 0606
Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
10:30AM-12:30PM
Abstract Number: 0316
Increased Synovial Inflammation, Xist Escape Gene Expression and Knee Pain in Females with Osteoarthritis
10:30AM-12:30PM
Abstract Number: 0196
Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
10:30AM-12:30PM
Abstract Number: 0490
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
10:30AM-12:30PM
Abstract Number: 0541
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
10:30AM-12:30PM
Abstract Number: 0105
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
10:30AM-12:30PM
Abstract Number: 0421
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
10:30AM-12:30PM
Abstract Number: 0265
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 0157
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0665
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
10:30AM-12:30PM
Abstract Number: 0259
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
10:30AM-12:30PM
Abstract Number: 0679
Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
10:30AM-12:30PM
Abstract Number: 0211
Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
10:30AM-12:30PM
Abstract Number: 0344
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
10:30AM-12:30PM
Abstract Number: 0036
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0070
Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0226
Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 0087
Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
10:30AM-12:30PM
Abstract Number: 0048
Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting
10:30AM-12:30PM
Abstract Number: 0298
Inter-rater Reliability of Hand-Held Dynamometry in Patients with Idiopathic Inflammatory Myopathy
10:30AM-12:30PM
Abstract Number: 0619
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
10:30AM-12:30PM
Abstract Number: 0090
Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts
10:30AM-12:30PM
Abstract Number: 0299
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 0770
Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 0481
Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
10:30AM-12:30PM
Abstract Number: 0740
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
10:30AM-12:30PM
Abstract Number: 0386
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis 
10:30AM-12:30PM
Abstract Number: 0515
Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
10:30AM-12:30PM
Abstract Number: 0188
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
10:30AM-12:30PM
Abstract Number: 0106
Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 0663
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
10:30AM-12:30PM
Abstract Number: 0102
Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
10:30AM-12:30PM
Abstract Number: 0612
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
10:30AM-12:30PM
Abstract Number: 0500
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
10:30AM-12:30PM
Abstract Number: 0754
Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
10:30AM-12:30PM
Abstract Number: 0424
Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
10:30AM-12:30PM
Abstract Number: 0405
Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study
10:30AM-12:30PM
Abstract Number: 0639
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
10:30AM-12:30PM
Abstract Number: 0002
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0325
Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
10:30AM-12:30PM
Abstract Number: 0012
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
10:30AM-12:30PM
Abstract Number: 0011
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
10:30AM-12:30PM
Abstract Number: 0137
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
10:30AM-12:30PM
Abstract Number: 0181
Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
10:30AM-12:30PM
Abstract Number: 0005
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
10:30AM-12:30PM
Abstract Number: 0730
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
10:30AM-12:30PM
Abstract Number: 0229
Leveraging the Electronic Medical Record to Improve the Rate of Discrete Data Collection in a Pediatric Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 0494
LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
10:30AM-12:30PM
Abstract Number: 0131
Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
10:30AM-12:30PM
Abstract Number: 0371
Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
10:30AM-12:30PM
Abstract Number: 0437
Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention
10:30AM-12:30PM
Abstract Number: PP08
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
10:30AM-12:30PM
Abstract Number: 0582
Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
10:30AM-12:30PM
Abstract Number: 0420
Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
10:30AM-12:30PM
Abstract Number: 0401
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
10:30AM-12:30PM
Abstract Number: 0023
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
10:30AM-12:30PM
Abstract Number: 0297
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
10:30AM-12:30PM
Abstract Number: 0597
Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0444
Low Disease Activity: Good Enough?
10:30AM-12:30PM
Abstract Number: 0656
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
10:30AM-12:30PM
Abstract Number: 0540
Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
10:30AM-12:30PM
Abstract Number: 0329
Machine Learning-Based Model to Predict Rapid Structural Progression in Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 0423
Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort
10:30AM-12:30PM
Abstract Number: 0706
Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study
10:30AM-12:30PM
Abstract Number: 0227
Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
10:30AM-12:30PM
Abstract Number: 0627
Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
10:30AM-12:30PM
Abstract Number: PP05
Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community
10:30AM-12:30PM
Abstract Number: 0427
Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
10:30AM-12:30PM
Abstract Number: PP04
MCTD and Aging – Resilience Required
10:30AM-12:30PM
Abstract Number: 0451
Menopause Status and Disease Activity in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0187
Message Testing in Online Recruitment Advertisements for a National Rheumatoid and Psoriatic Arthritis Study
10:30AM-12:30PM
Abstract Number: 0034
Meta-Analysis of GWAS data from 10,003 Sjögren’s Disease Cases Identifies Thirteen Sjögren’s Risk Loci.
10:30AM-12:30PM
Abstract Number: 0031
Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
10:30AM-12:30PM
Abstract Number: 0322
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
10:30AM-12:30PM
Abstract Number: 0054
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
10:30AM-12:30PM
Abstract Number: 0454
Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
10:30AM-12:30PM
Abstract Number: 0553
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
10:30AM-12:30PM
Abstract Number: 0047
Monocyte Transcriptomic Signatures Uncover Potential Pathogenic Mechanisms of the APOL1 High Risk Genotype (HRG)
10:30AM-12:30PM
Abstract Number: 0237
Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights
10:30AM-12:30PM
Abstract Number: 0150
Mortality in Anca-associated Vasculitis
10:30AM-12:30PM
Abstract Number: 0235
Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years
10:30AM-12:30PM
Abstract Number: 0009
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
10:30AM-12:30PM
Abstract Number: 0268
Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
10:30AM-12:30PM
Abstract Number: 0485
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
10:30AM-12:30PM
Abstract Number: 0295
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
10:30AM-12:30PM
Abstract Number: 0380
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 0705
Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
10:30AM-12:30PM
Abstract Number: 0546
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
10:30AM-12:30PM
Abstract Number: 0385
Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study
10:30AM-12:30PM
Abstract Number: PP03
My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis
10:30AM-12:30PM
Abstract Number: 0220
National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
10:30AM-12:30PM
Abstract Number: 0062
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
10:30AM-12:30PM
Abstract Number: 0184
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
10:30AM-12:30PM
Abstract Number: 0616
Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
10:30AM-12:30PM
Abstract Number: 0609
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
10:30AM-12:30PM
Abstract Number: 0723
Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
10:30AM-12:30PM
Abstract Number: 0134
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
10:30AM-12:30PM
Abstract Number: 0675
Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
10:30AM-12:30PM
Abstract Number: 0377
New efforts to incorporate patient-reported outcomes into clinical trials for lupus therapeutics
10:30AM-12:30PM
Abstract Number: 0014
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
10:30AM-12:30PM
Abstract Number: 0301
Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release
10:30AM-12:30PM
Abstract Number: 0249
Obesity as a possible confusion factor in the scleroderma pattern
10:30AM-12:30PM
Abstract Number: 0650
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
10:30AM-12:30PM
Abstract Number: 0654
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
10:30AM-12:30PM
Abstract Number: 0272
Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice
10:30AM-12:30PM
Abstract Number: 0499
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
10:30AM-12:30PM
Abstract Number: 0164
Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0253
Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
10:30AM-12:30PM
Abstract Number: 0183
Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
10:30AM-12:30PM
Abstract Number: 0439
Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
10:30AM-12:30PM
Abstract Number: 0140
Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
10:30AM-12:30PM
Abstract Number: 0411
Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
10:30AM-12:30PM
Abstract Number: 0416
Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
10:30AM-12:30PM
Abstract Number: 0492
Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
10:30AM-12:30PM
Abstract Number: 0397
Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
10:30AM-12:30PM
Abstract Number: 0199
Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
10:30AM-12:30PM
Abstract Number: 0561
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
10:30AM-12:30PM
Abstract Number: 0153
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
10:30AM-12:30PM
Abstract Number: 0370
Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
10:30AM-12:30PM
Abstract Number: 0175
Patient Satisfaction with a New Patient Video Triage Program
10:30AM-12:30PM
Abstract Number: 0594
Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
10:30AM-12:30PM
Abstract Number: 0292
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 0747
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
10:30AM-12:30PM
Abstract Number: 0313
People with Knee Osteoarthritis Infrequently Seek Medical Care for Arthritis, Even Those With Severe Disease
10:30AM-12:30PM
Abstract Number: 0321
Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data from the Osteoarthritis Initiative
10:30AM-12:30PM
Abstract Number: 0165
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
10:30AM-12:30PM
Abstract Number: 0258
Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
10:30AM-12:30PM
Abstract Number: 0126
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
10:30AM-12:30PM
Abstract Number: 0468
Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort
10:30AM-12:30PM
Abstract Number: 0350
Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
10:30AM-12:30PM
Abstract Number: 0580
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
10:30AM-12:30PM
Abstract Number: 0577
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
10:30AM-12:30PM
Abstract Number: 0664
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
10:30AM-12:30PM
Abstract Number: 0498
Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
10:30AM-12:30PM
Abstract Number: 0267
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
10:30AM-12:30PM
Abstract Number: 0501
Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
10:30AM-12:30PM
Abstract Number: 0555
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
10:30AM-12:30PM
Abstract Number: 0493
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
10:30AM-12:30PM
Abstract Number: 0570
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
10:30AM-12:30PM
Abstract Number: 0466
Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
10:30AM-12:30PM
Abstract Number: 0318
Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
10:30AM-12:30PM
Abstract Number: 0276
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
10:30AM-12:30PM
Abstract Number: 0130
Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome
10:30AM-12:30PM
Abstract Number: 0624
Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria
10:30AM-12:30PM
Abstract Number: 0145
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
10:30AM-12:30PM
Abstract Number: 0225
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
10:30AM-12:30PM
Abstract Number: 0151
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
10:30AM-12:30PM
Abstract Number: 0601
Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
10:30AM-12:30PM
Abstract Number: 0262
Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
10:30AM-12:30PM
Abstract Number: 0414
Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study
10:30AM-12:30PM
Abstract Number: 0111
Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures
10:30AM-12:30PM
Abstract Number: 0566
Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
10:30AM-12:30PM
Abstract Number: 0288
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
10:30AM-12:30PM
Abstract Number: 0245
Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
10:30AM-12:30PM
Abstract Number: 0394
Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis
10:30AM-12:30PM
Abstract Number: 0682
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
10:30AM-12:30PM
Abstract Number: 0657
Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
10:30AM-12:30PM
Abstract Number: 0159
Prenatal and Early-Life Environmental Exposures in Juvenile-Onset Systemic Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0293
Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis
10:30AM-12:30PM
Abstract Number: 0544
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
10:30AM-12:30PM
Abstract Number: 0749
Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0745
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
10:30AM-12:30PM
Abstract Number: 0178
Prevalence and factors associated with virtual rheumatology care utilization in a national population of Veterans with RA
10:30AM-12:30PM
Abstract Number: 0534
Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort
10:30AM-12:30PM
Abstract Number: 0638
Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
10:30AM-12:30PM
Abstract Number: 0330
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
10:30AM-12:30PM
Abstract Number: 0382
Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
10:30AM-12:30PM
Abstract Number: 0052
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
10:30AM-12:30PM
Abstract Number: 0123
Prognosis of Cardiac Involvement in Antiphospholipid Syndrome
10:30AM-12:30PM
Abstract Number: 0185
Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision
10:30AM-12:30PM
Abstract Number: 0206
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
10:30AM-12:30PM
Abstract Number: 0032
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
10:30AM-12:30PM
Abstract Number: 0112
Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0721
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
10:30AM-12:30PM
Abstract Number: 0457
Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
10:30AM-12:30PM
Abstract Number: 0006
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0767
Quality of Life in Patients with Rheumatoid Arthritis with Foot and Ankle Involvement
10:30AM-12:30PM
Abstract Number: 0396
Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
10:30AM-12:30PM
Abstract Number: 0690
Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
10:30AM-12:30PM
Abstract Number: 0674
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
10:30AM-12:30PM
Abstract Number: 0482
R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 0066
RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
10:30AM-12:30PM
Abstract Number: 0478
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0390
Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
10:30AM-12:30PM
Abstract Number: 0771
Radiographic Knee Osteoarthritis and Corticosteroid Injection Use: The Moderating Role of Physical Activity
10:30AM-12:30PM
Abstract Number: 0524
Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
10:30AM-12:30PM
Abstract Number: 0552
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0261
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
10:30AM-12:30PM
Abstract Number: 0533
Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
10:30AM-12:30PM
Abstract Number: 0648
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
10:30AM-12:30PM
Abstract Number: 0554
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
10:30AM-12:30PM
Abstract Number: 0738
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0726
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
10:30AM-12:30PM
Abstract Number: 0513
Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
10:30AM-12:30PM
Abstract Number: 0502
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
10:30AM-12:30PM
Abstract Number: 0661
Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
10:30AM-12:30PM
Abstract Number: 0238
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
10:30AM-12:30PM
Abstract Number: 0578
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
10:30AM-12:30PM
Abstract Number: 0474
Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
10:30AM-12:30PM
Abstract Number: 0429
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
10:30AM-12:30PM
Abstract Number: 0369
Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0201
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
10:30AM-12:30PM
Abstract Number: 0572
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
10:30AM-12:30PM
Abstract Number: 0400
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 0084
Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
10:30AM-12:30PM
Abstract Number: 0587
Regulatory Role of IL­17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
10:30AM-12:30PM
Abstract Number: 0762
Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
10:30AM-12:30PM
Abstract Number: 0666
Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
10:30AM-12:30PM
Abstract Number: 0056
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
10:30AM-12:30PM
Abstract Number: 0465
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
10:30AM-12:30PM
Abstract Number: 0667
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
10:30AM-12:30PM
Abstract Number: 0430
Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
10:30AM-12:30PM
Abstract Number: 0197
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
10:30AM-12:30PM
Abstract Number: 0147
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
10:30AM-12:30PM
Abstract Number: 0170
Rheumatoid arthritis, serologic status and risk of heart failure: A national cohort study
10:30AM-12:30PM
Abstract Number: 0074
Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance
10:30AM-12:30PM
Abstract Number: 0461
Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0161
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
10:30AM-12:30PM
Abstract Number: 0459
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 0402
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
10:30AM-12:30PM
Abstract Number: 0142
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
10:30AM-12:30PM
Abstract Number: 0203
Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0621
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
10:30AM-12:30PM
Abstract Number: 0479
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
10:30AM-12:30PM
Abstract Number: 0724
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
10:30AM-12:30PM
Abstract Number: 0168
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
10:30AM-12:30PM
Abstract Number: 0135
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
10:30AM-12:30PM
Abstract Number: 0107
Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0341
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
10:30AM-12:30PM
Abstract Number: 0765
Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study
10:30AM-12:30PM
Abstract Number: 0641
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
10:30AM-12:30PM
Abstract Number: 0331
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
10:30AM-12:30PM
Abstract Number: 0236
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 0453
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
10:30AM-12:30PM
Abstract Number: 0257
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
10:30AM-12:30PM
Abstract Number: 0483
Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
10:30AM-12:30PM
Abstract Number: 0239
Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
10:30AM-12:30PM
Abstract Number: 0486
Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
10:30AM-12:30PM
Abstract Number: 0332
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0202
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
10:30AM-12:30PM
Abstract Number: 0064
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
10:30AM-12:30PM
Abstract Number: 0264
Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
10:30AM-12:30PM
Abstract Number: 0280
Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
10:30AM-12:30PM
Abstract Number: 0508
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
10:30AM-12:30PM
Abstract Number: 0042
Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0200
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
10:30AM-12:30PM
Abstract Number: 0755
Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0622
Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
10:30AM-12:30PM
Abstract Number: 0019
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 0085
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 0560
Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
10:30AM-12:30PM
Abstract Number: 0043
Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
10:30AM-12:30PM
Abstract Number: 0124
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
10:30AM-12:30PM
Abstract Number: 0127
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
10:30AM-12:30PM
Abstract Number: 0571
Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0118
Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
10:30AM-12:30PM
Abstract Number: 0725
Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 0110
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
10:30AM-12:30PM
Abstract Number: 0093
Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0567
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
10:30AM-12:30PM
Abstract Number: 0504
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0026
Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
10:30AM-12:30PM
Abstract Number: 0069
Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions
10:30AM-12:30PM
Abstract Number: 0523
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
10:30AM-12:30PM
Abstract Number: 0051
Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice
10:30AM-12:30PM
Abstract Number: 0289
Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
10:30AM-12:30PM
Abstract Number: 0756
Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients
10:30AM-12:30PM
Abstract Number: 0608
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
10:30AM-12:30PM
Abstract Number: 0327
Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort
10:30AM-12:30PM
Abstract Number: 0598
Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0511
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 0715
Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France
10:30AM-12:30PM
Abstract Number: 0595
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
10:30AM-12:30PM
Abstract Number: 0683
Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0092
SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging
10:30AM-12:30PM
Abstract Number: 0463
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 0464
Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
10:30AM-12:30PM
Abstract Number: 0214
Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
10:30AM-12:30PM
Abstract Number: 0615
Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
10:30AM-12:30PM
Abstract Number: 0709
Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
10:30AM-12:30PM
Abstract Number: 0685
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
10:30AM-12:30PM
Abstract Number: 0678
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
10:30AM-12:30PM
Abstract Number: 0055
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
10:30AM-12:30PM
Abstract Number: 0545
Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
10:30AM-12:30PM
Abstract Number: 0452
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
10:30AM-12:30PM
Abstract Number: 0434
The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
10:30AM-12:30PM
Abstract Number: 0171
The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia
10:30AM-12:30PM
Abstract Number: 0412
The Association of Obesity with Juvenile Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0098
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
10:30AM-12:30PM
Abstract Number: 0588
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
10:30AM-12:30PM
Abstract Number: 0731
The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0760
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0651
The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0207
The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
10:30AM-12:30PM
Abstract Number: 0450
The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0671
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
10:30AM-12:30PM
Abstract Number: 0169
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
10:30AM-12:30PM
Abstract Number: 0125
The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 0460
The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0415
The Impact of Social Vulnerability Index Scores in Pediatric Uveitis
10:30AM-12:30PM
Abstract Number: 0522
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0053
The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
10:30AM-12:30PM
Abstract Number: 0428
The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
10:30AM-12:30PM
Abstract Number: 0440
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
10:30AM-12:30PM
Abstract Number: 0283
The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
10:30AM-12:30PM
Abstract Number: 0120
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
10:30AM-12:30PM
Abstract Number: 0121
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
10:30AM-12:30PM
Abstract Number: 0610
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
10:30AM-12:30PM
Abstract Number: 0080
The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0256
The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
10:30AM-12:30PM
Abstract Number: 0122
The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
10:30AM-12:30PM
Abstract Number: 0757
The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.
10:30AM-12:30PM
Abstract Number: 0407
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
10:30AM-12:30PM
Abstract Number: 0605
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
10:30AM-12:30PM
Abstract Number: 0620
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
10:30AM-12:30PM
Abstract Number: 0618
Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
10:30AM-12:30PM
Abstract Number: 0100
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
10:30AM-12:30PM
Abstract Number: 0119
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0099
Time course and impact of  IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
10:30AM-12:30PM
Abstract Number: 0311
Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model
10:30AM-12:30PM
Abstract Number: 0223
Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
10:30AM-12:30PM
Abstract Number: 0050
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
10:30AM-12:30PM
Abstract Number: 0057
TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
10:30AM-12:30PM
Abstract Number: 0739
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
10:30AM-12:30PM
Abstract Number: 0426
Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
10:30AM-12:30PM
Abstract Number: 0688
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
10:30AM-12:30PM
Abstract Number: 0600
Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
10:30AM-12:30PM
Abstract Number: 0058
Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
10:30AM-12:30PM
Abstract Number: 0081
Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0320
Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease
10:30AM-12:30PM
Abstract Number: 0077
Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
10:30AM-12:30PM
Abstract Number: 0542
Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
10:30AM-12:30PM
Abstract Number: 0361
Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
10:30AM-12:30PM
Abstract Number: 0514
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
10:30AM-12:30PM
Abstract Number: 0684
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
10:30AM-12:30PM
Abstract Number: 0274
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
10:30AM-12:30PM
Abstract Number: 0603
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
10:30AM-12:30PM
Abstract Number: 0694
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
10:30AM-12:30PM
Abstract Number: 0703
Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
10:30AM-12:30PM
Abstract Number: 0163
Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
10:30AM-12:30PM
Abstract Number: 0458
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0419
Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
10:30AM-12:30PM
Abstract Number: 0521
Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
10:30AM-12:30PM
Abstract Number: 0349
Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
10:30AM-12:30PM
Abstract Number: 0068
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0071
Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
10:30AM-12:30PM
Abstract Number: 0543
Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
10:30AM-12:30PM
Abstract Number: 0302
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
10:30AM-12:30PM
Abstract Number: 0686
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
10:30AM-12:30PM
Abstract Number: 0234
Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis
10:30AM-12:30PM
Abstract Number: 0247
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
10:30AM-12:30PM
Abstract Number: 0505
Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
10:30AM-12:30PM
Abstract Number: 0716
Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
10:30AM-12:30PM
Abstract Number: 0195
Utility of Repeat ANA Testing
10:30AM-12:30PM
Abstract Number: 0186
Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
10:30AM-12:30PM
Abstract Number: 0198
Variation in RA disease activity measure assessment and treatment change documentation in virtual vs in-office rheumatology visits
10:30AM-12:30PM
Abstract Number: 0710
Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
10:30AM-12:30PM
Abstract Number: 0611
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
10:30AM-12:30PM
Abstract Number: 0768
Veteran Rehabilitation, Physical Therapy Care Delivery, and Outcomes after Total Knee Arthroplasty
10:30AM-12:30PM
Abstract Number: 0314
What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
10:30AM-12:30PM
Abstract Number: 0707
When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
10:30AM-12:30PM
Abstract Number: 0139
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
10:30AM-12:30PM
Abstract Number: PP02
When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
10:30AM-12:30PM
Abstract Number: PP01
When You Become the Story: A Journalist’s Approach to Managing Complex Care
10:30AM-12:30PM
Abstract Number: 0539
Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
10:30AM-12:30PM
Abstract Number: 0391
Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
10:30AM-12:30PM
Abstract Number: 0436
Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
10:30AM-12:30PM
Abstract Number: 0575
Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
10:30AM-12:30PM
Abstract Number: 0010
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 0113
ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
10:30AM-12:30PM
Abstract Number: 0628
Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
10:45AM-11:00AM
Abstract Number: 0776
Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial
1:00PM-1:15PM
Abstract Number: 0801
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
1:00PM-1:15PM
Abstract Number: 0807
Deciphering Synovitis in Systemic Sclerosis
1:00PM-1:15PM
Abstract Number: 0777
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
1:00PM-1:15PM
Abstract Number: 0795
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
1:00PM-1:15PM
Abstract Number: 0783
Pain reduction and functional improvements following a non-invasive biomechanical intervention for gait rehabilitation may explain a reduction in healthcare claims. An observational study
1:00PM-1:15PM
Abstract Number: 0789
Short Form 36 (SF-36) Health Survey Questionnaire in Health-Related Quality of Life Assessment in Patients with Inflammatory Myopathies
1:00PM-1:15PM
Abstract Number: 0788
Spatiotemporal Gait Differences Between Fallers and Non-Fallers in People with Knee Osteoarthritis
1:15PM-1:30PM
Abstract Number: 0778
Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome
1:15PM-1:30PM
Abstract Number: 0796
Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
1:15PM-1:30PM
Abstract Number: 0790
Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data
1:15PM-1:30PM
Abstract Number: 0784
Physical Activity and Exercise Therapy Reduce the Transition from Acute to Chronic Low Back Pain in the Community
1:15PM-1:30PM
Abstract Number: 0802
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
1:15PM-1:30PM
Abstract Number: 0808
Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
1:30PM-1:45PM
Abstract Number: 0791
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
1:30PM-1:45PM
Abstract Number: 0809
Human blood vessel organoids as a model of vasculopathy in systemic sclerosis
1:30PM-1:45PM
Abstract Number: 0803
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
1:30PM-1:45PM
Abstract Number: 0779
Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever
1:30PM-1:45PM
Abstract Number: 0785
It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes
1:30PM-1:45PM
Abstract Number: 0797
Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining
1:45PM-2:00PM
Abstract Number: 0786
A Machine Learning Approach to Understand Age as a Risk Factor for Complications After Total Hip Arthroplasty
1:45PM-2:00PM
Abstract Number: 0780
Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
1:45PM-2:00PM
Abstract Number: 0804
Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
1:45PM-2:00PM
Abstract Number: 0798
Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity
1:45PM-2:00PM
Abstract Number: 0792
Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases
1:45PM-2:00PM
Abstract Number: 0810
Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement
2:00PM-2:15PM
Abstract Number: 0799
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
2:00PM-2:15PM
Abstract Number: 0781
Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease
2:00PM-2:15PM
Abstract Number: 0805
Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
2:00PM-2:15PM
Abstract Number: 0811
SSc Skin Cell Atlas: a Scalable Web Portal for scRNA-Seq Analysis
2:00PM-2:15PM
Abstract Number: 0787
The Cost-effectiveness of Physical Therapy for Patients with Meniscal Tear and Osteoarthritis
2:00PM-2:15PM
Abstract Number: 0793
The weight of the past: how trauma and resilience shape medication adherence in SLE
2:15PM-2:30PM
Abstract Number: 0812
Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis
2:15PM-2:30PM
Abstract Number: 0806
Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
2:15PM-2:30PM
Abstract Number: 0782
Expansion of T-bet⁺ Age-Associated B Cells Is Associated with Clinical Complications in Still’s Disease
2:15PM-2:30PM
Abstract Number: 0800
Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
2:15PM-2:30PM
Abstract Number: 0794
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
3:00PM-3:15PM
Abstract Number: 0831
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
3:00PM-3:15PM
Abstract Number: 0843
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
3:00PM-3:15PM
Abstract Number: 0813
Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study
3:00PM-3:15PM
Abstract Number: 0825
Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
3:00PM-3:15PM
Abstract Number: 0837
Risk of New Proteinuria in Next Ten Years in SLE
3:00PM-3:15PM
Abstract Number: 0819
Subcellular resolution spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis
3:15PM-3:30PM
Abstract Number: 0838
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
3:15PM-3:30PM
Abstract Number: 0832
Elevated serum peptidylarginine deiminase 4 (PAD4) levels in anti-CCP antibody positive at-risk individuals with arthralgia who progress to rheumatoid arthritis.
3:15PM-3:30PM
Abstract Number: 0826
Impact of Large Language Models on Diagnostic Reasoning of Medical Students in Rheumatology: A Randomized Trial
3:15PM-3:30PM
Abstract Number: 0844
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
3:15PM-3:30PM
Abstract Number: 0820
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
3:15PM-3:30PM
Abstract Number: 0814
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
3:30PM-3:45PM
Abstract Number: 0821
Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease
3:30PM-3:45PM
Abstract Number: 0845
Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
3:30PM-3:45PM
Abstract Number: 0815
Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
3:30PM-3:45PM
Abstract Number: 0839
Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
3:30PM-3:45PM
Abstract Number: 0833
Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA
3:30PM-3:45PM
Abstract Number: 0827
Utilization of American College of Rheumatology Vaccination Guidelines in Clinic: A Needs Assessment in an Internal Medicine Residency Program
3:45PM-4:00PM
Abstract Number: 0846
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
3:45PM-4:00PM
Abstract Number: 0822
Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
3:45PM-4:00PM
Abstract Number: 0834
Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
3:45PM-4:00PM
Abstract Number: 0816
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
3:45PM-4:00PM
Abstract Number: 0840
Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
3:45PM-4:00PM
Abstract Number: 0828
Two Common AI Models Create Poor Rheumatology Board Style Questions
4:00PM-4:15PM
Abstract Number: 0841
Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
4:00PM-4:15PM
Abstract Number: 0835
IgG Glycome In Early Rheumatoid Arthritis Differs From Matched Controls and Links Less Lean Mass to an Early Aging Phenotype
4:00PM-4:15PM
Abstract Number: 0847
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
4:00PM-4:15PM
Abstract Number: 0823
Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes
4:00PM-4:15PM
Abstract Number: 0817
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
4:00PM-4:15PM
Abstract Number: 0829
Multi-Center Use of an Online Case-Based Simulation to Evaluate Medical Trainee Use of Diagnostic Imaging and Lab Tests to Correctly Diagnose MSK Complaints
4:15PM-4:30PM
Abstract Number: 0842
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
4:15PM-4:30PM
Abstract Number: 0824
Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
4:15PM-4:30PM
Abstract Number: 0836
Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis
4:15PM-4:30PM
Abstract Number: 0830
Rheum2Listen: Leveraging Podcasts to Teach Rheumatology to Internal Medical Residents
4:15PM-4:30PM
Abstract Number: 0818
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
4:15PM-4:30PM
Abstract Number: 0848
Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates
8:00AM-8:15AM
Abstract Number: 0849
Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis
8:15AM-8:30AM
Abstract Number: 0850
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
8:30AM-8:45AM
Abstract Number: 0851
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
8:45AM-9:00AM
Abstract Number: 0852
LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
9:00AM-9:15AM
Abstract Number: 0853
Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
9:15AM-9:30AM
Abstract Number: 0854
The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
10:00AM-10:15AM
Abstract Number: 0855
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
10:00AM-10:15AM
Abstract Number: 0861
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
10:00AM-10:15AM
Abstract Number: 0885
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
10:00AM-10:15AM
Abstract Number: 0891
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
10:00AM-10:15AM
Abstract Number: 0867
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
10:00AM-10:15AM
Abstract Number: 0873
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
10:00AM-10:15AM
Abstract Number: 0879
Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort
10:15AM-10:30AM
Abstract Number: 0886
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
10:15AM-10:30AM
Abstract Number: 0880
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
10:15AM-10:30AM
Abstract Number: 0874
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
10:15AM-10:30AM
Abstract Number: 0862
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
10:15AM-10:30AM
Abstract Number: 0856
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
10:15AM-10:30AM
Abstract Number: 0892
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
10:30AM-12:30PM
Abstract Number: 1052
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
10:30AM-12:30PM
Abstract Number: 1375
86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
10:30AM-12:30PM
Abstract Number: 1287
A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
10:30AM-12:30PM
Abstract Number: 1406
A Combined Score of Facet Joint Ankylosis and Syndesmophyte Development Correlates Well with Spinal Mobility in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1405
A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1395
A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 1151
A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1000
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
10:30AM-12:30PM
Abstract Number: 1626
A Delphi Exercise Informing the Development of Criteria to Measure Response to Treatment in Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 0915
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
10:30AM-12:30PM
Abstract Number: 1135
A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate
10:30AM-12:30PM
Abstract Number: 1468
A HIPAA-Compliant LLM for Personalized Therapeutic Decision-Making in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1609
A Multicenter Prospective Longitudinal Observational Study To Determine Safety Of Extended Treatment With Rituximab In Maintaining Remission In Patients With ANCA Associated Vasculitis (AAV) – An Interim Analysis
10:30AM-12:30PM
Abstract Number: 1420
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 0902
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
10:30AM-12:30PM
Abstract Number: 1568
A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level
10:30AM-12:30PM
Abstract Number: 0911
A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
10:30AM-12:30PM
Abstract Number: 0946
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
10:30AM-12:30PM
Abstract Number: 1172
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 1133
A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition
10:30AM-12:30PM
Abstract Number: 1144
A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function
10:30AM-12:30PM
Abstract Number: 1122
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
10:30AM-12:30PM
Abstract Number: 1574
A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease
10:30AM-12:30PM
Abstract Number: 1645
A sex-modified association between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) blood concentration and prevalent arthritis among young and middle-aged US adults
10:30AM-12:30PM
Abstract Number: 0964
A Single-Cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-Specific Pathways in Autoimmune Disorders
10:30AM-12:30PM
Abstract Number: 1376
A Systematic Literature Review on the Economic Burden of Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1627
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
10:30AM-12:30PM
Abstract Number: 1614
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
10:30AM-12:30PM
Abstract Number: 1170
A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort
10:30AM-12:30PM
Abstract Number: 1124
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
10:30AM-12:30PM
Abstract Number: 1022
Abuse in Rheumatic Diseases: Associations with Depression, Disability, and Psychosocial Risk Factors
10:30AM-12:30PM
Abstract Number: 1007
Accelerometry-Derived Activity and Sleep Patterns in the NIH All of Us Cohort: Insights and Predictive Potential for Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 1084
Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
10:30AM-12:30PM
Abstract Number: 1349
Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-To-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-year Outcomes from the UPHOLD Study
10:30AM-12:30PM
Abstract Number: 1531
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
10:30AM-12:30PM
Abstract Number: 1497
Acute Care Utilization in Patients with Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1290
Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
10:30AM-12:30PM
Abstract Number: 1065
Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1006
AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody
10:30AM-12:30PM
Abstract Number: 1013
All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states
10:30AM-12:30PM
Abstract Number: 0899
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
10:30AM-12:30PM
Abstract Number: 1542
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
10:30AM-12:30PM
Abstract Number: 0990
An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model
10:30AM-12:30PM
Abstract Number: 1178
An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)
10:30AM-12:30PM
Abstract Number: 1044
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
10:30AM-12:30PM
Abstract Number: 1274
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
10:30AM-12:30PM
Abstract Number: 1436
Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
10:30AM-12:30PM
Abstract Number: 1547
Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
10:30AM-12:30PM
Abstract Number: 1548
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
10:30AM-12:30PM
Abstract Number: 1428
Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
10:30AM-12:30PM
Abstract Number: 1331
Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 1559
Anti-Cytolethal Distending Toxin Antibodies in Systemic Sclerosis: Associations with Gastrointestinal Disease and Immune Dysregulation
10:30AM-12:30PM
Abstract Number: 1219
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
10:30AM-12:30PM
Abstract Number: 1512
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
10:30AM-12:30PM
Abstract Number: 1607
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
10:30AM-12:30PM
Abstract Number: 1162
Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease
10:30AM-12:30PM
Abstract Number: 1188
Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
10:30AM-12:30PM
Abstract Number: 0897
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
10:30AM-12:30PM
Abstract Number: 1351
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
10:30AM-12:30PM
Abstract Number: 1080
Are Minority Populations Truly Vaccine Hesitant? A Provider-Based Approach to RSV Vaccine Uptake Suggests Otherwise.
10:30AM-12:30PM
Abstract Number: 1210
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
10:30AM-12:30PM
Abstract Number: 1066
Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
10:30AM-12:30PM
Abstract Number: 1059
Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
10:30AM-12:30PM
Abstract Number: 1391
Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
10:30AM-12:30PM
Abstract Number: 1154
Assessment Of Damage Using The IgG4-Related Disease Damage Index.
10:30AM-12:30PM
Abstract Number: 1422
Assessment of difficulties, modifications and use of work adaptations in patients with axial spondyloarthritis: validation of the DificuLtAx and ModAL questionnaires
10:30AM-12:30PM
Abstract Number: 1333
Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
10:30AM-12:30PM
Abstract Number: 1041
Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
10:30AM-12:30PM
Abstract Number: 1225
Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1016
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 1128
Association between leptin levels, body mass index and health-related quality of life in patients with gout
10:30AM-12:30PM
Abstract Number: 1326
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 1249
Association between Positive Emotions and Physical Function in Early Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 1105
Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors
10:30AM-12:30PM
Abstract Number: 1025
Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
10:30AM-12:30PM
Abstract Number: 1068
Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
10:30AM-12:30PM
Abstract Number: 1557
Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1635
Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1641
Association of Area Socioeconomic Deprivation with Community Mobility in a Diverse Cohort of Individuals with SLE
10:30AM-12:30PM
Abstract Number: 1389
Association Of Dry Eye Severity With Salivary Flow In Patients With Primary Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 1540
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
10:30AM-12:30PM
Abstract Number: 1590
Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
10:30AM-12:30PM
Abstract Number: 1214
Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis
10:30AM-12:30PM
Abstract Number: 1634
Association of Systemic Lupus Erythematosus With Incident Heart Failure Requiring Hospitalization
10:30AM-12:30PM
Abstract Number: 1565
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
10:30AM-12:30PM
Abstract Number: 1146
Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study
10:30AM-12:30PM
Abstract Number: 1019
Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
10:30AM-12:30PM
Abstract Number: 1100
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0958
Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1002
ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
10:30AM-12:30PM
Abstract Number: 1476
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
10:30AM-12:30PM
Abstract Number: 1374
AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
10:30AM-12:30PM
Abstract Number: 1107
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
10:30AM-12:30PM
Abstract Number: 1108
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
10:30AM-12:30PM
Abstract Number: 1045
Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
10:30AM-12:30PM
Abstract Number: 1533
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
10:30AM-12:30PM
Abstract Number: 1209
Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
10:30AM-12:30PM
Abstract Number: 1241
Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life
10:30AM-12:30PM
Abstract Number: 1400
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
10:30AM-12:30PM
Abstract Number: 1449
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 1439
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
10:30AM-12:30PM
Abstract Number: 1451
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 1297
Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.
10:30AM-12:30PM
Abstract Number: 1510
Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1166
Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
10:30AM-12:30PM
Abstract Number: 1602
Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
10:30AM-12:30PM
Abstract Number: 1042
Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
10:30AM-12:30PM
Abstract Number: 1498
Both Race and Socioeconomic Status Affect Mortality in SLE
10:30AM-12:30PM
Abstract Number: 1112
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
10:30AM-12:30PM
Abstract Number: 0996
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
10:30AM-12:30PM
Abstract Number: 1264
Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
10:30AM-12:30PM
Abstract Number: 1050
Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
10:30AM-12:30PM
Abstract Number: 1085
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
10:30AM-12:30PM
Abstract Number: 1243
Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
10:30AM-12:30PM
Abstract Number: 1394
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
10:30AM-12:30PM
Abstract Number: 1477
Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
10:30AM-12:30PM
Abstract Number: 1252
Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
10:30AM-12:30PM
Abstract Number: 1569
Can We Use Patient Reported Outcomes For Home-monitoring in SSc?
10:30AM-12:30PM
Abstract Number: 1392
Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
10:30AM-12:30PM
Abstract Number: 1046
Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
10:30AM-12:30PM
Abstract Number: 1039
CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
10:30AM-12:30PM
Abstract Number: 1334
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
10:30AM-12:30PM
Abstract Number: 1182
Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
10:30AM-12:30PM
Abstract Number: 1397
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
10:30AM-12:30PM
Abstract Number: 0912
CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus
10:30AM-10:45AM
Abstract Number: 0857
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
10:30AM-12:30PM
Abstract Number: 1005
CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
10:30AM-12:30PM
Abstract Number: 1070
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
10:30AM-12:30PM
Abstract Number: 1029
Cervical cancer screening rates in Korean women of childbearing age with systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1094
Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
10:30AM-12:30PM
Abstract Number: 1472
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
10:30AM-12:30PM
Abstract Number: 1109
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
10:30AM-12:30PM
Abstract Number: 1386
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
10:30AM-12:30PM
Abstract Number: 1064
Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry
10:30AM-12:30PM
Abstract Number: 1628
Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
10:30AM-12:30PM
Abstract Number: 1437
Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
10:30AM-12:30PM
Abstract Number: 1385
Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 1111
Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
10:30AM-12:30PM
Abstract Number: 1102
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
10:30AM-12:30PM
Abstract Number: 1335
Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis
10:30AM-12:30PM
Abstract Number: 1292
Childhood-onset Behçet’s disease: HLA alleles role on diagnosis and treatment in a Latin American tertiary center
10:30AM-12:30PM
Abstract Number: 1230
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
10:30AM-12:30PM
Abstract Number: 1553
Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis
10:30AM-10:45AM
Abstract Number: 0881
Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 1412
Classification of sacroiliits using an artificial intelligence model
10:30AM-12:30PM
Abstract Number: 1163
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
10:30AM-12:30PM
Abstract Number: 1452
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
10:30AM-12:30PM
Abstract Number: 1158
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
10:30AM-12:30PM
Abstract Number: 1167
Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study
10:30AM-12:30PM
Abstract Number: 1458
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 1126
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1284
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1189
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1305
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
10:30AM-12:30PM
Abstract Number: 1647
Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
10:30AM-12:30PM
Abstract Number: 1575
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
10:30AM-12:30PM
Abstract Number: 1181
Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines
10:30AM-12:30PM
Abstract Number: 1020
Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
10:30AM-12:30PM
Abstract Number: 1277
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 1605
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
10:30AM-12:30PM
Abstract Number: 1054
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
10:30AM-12:30PM
Abstract Number: 1417
Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 1023
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1224
Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
10:30AM-12:30PM
Abstract Number: 1161
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
10:30AM-12:30PM
Abstract Number: 1359
Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1494
Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences
10:30AM-12:30PM
Abstract Number: 1495
Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
10:30AM-12:30PM
Abstract Number: 1089
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
10:30AM-12:30PM
Abstract Number: 1638
Comparison and Assessment of the All of Us Dataset for Epidemiologic Studies of Systemic Lupus Erythematosus (SLE) Among African American Women
10:30AM-12:30PM
Abstract Number: 1593
Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
10:30AM-12:30PM
Abstract Number: 1440
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1473
Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0932
Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis
10:30AM-12:30PM
Abstract Number: 1572
Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1639
Concordance of Self-Reported Physical Functioning and Physical Performance in SLE: A Cross-Cohort Analysis
10:30AM-12:30PM
Abstract Number: 1010
Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
10:30AM-12:30PM
Abstract Number: 1478
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1620
Correlation Between Histopathological Findings and PET-CT Results in Patients With Inflammatory Aortitis
10:30AM-12:30PM
Abstract Number: 1366
Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
10:30AM-12:30PM
Abstract Number: 0907
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
10:30AM-12:30PM
Abstract Number: 1207
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
10:30AM-12:30PM
Abstract Number: 1152
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
10:30AM-12:30PM
Abstract Number: 1599
Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
10:30AM-12:30PM
Abstract Number: 1390
Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 0901
Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders
10:30AM-12:30PM
Abstract Number: 1132
DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk
10:30AM-12:30PM
Abstract Number: 1311
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
10:30AM-12:30PM
Abstract Number: 1484
Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
10:30AM-12:30PM
Abstract Number: 1567
Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease
10:30AM-12:30PM
Abstract Number: 1622
Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib
10:30AM-12:30PM
Abstract Number: 1411
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
10:30AM-12:30PM
Abstract Number: 1387
Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
10:30AM-12:30PM
Abstract Number: 1035
Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
10:30AM-12:30PM
Abstract Number: 1060
Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1554
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
10:30AM-12:30PM
Abstract Number: 1496
Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
10:30AM-12:30PM
Abstract Number: 1235
Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?
10:30AM-12:30PM
Abstract Number: 1071
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
10:30AM-12:30PM
Abstract Number: 0983
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
10:30AM-12:30PM
Abstract Number: 0905
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1073
Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 0910
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 1268
Development of the LupusCoach Chatbot: Results of a Focus Group
10:30AM-12:30PM
Abstract Number: 1318
Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients
10:30AM-12:30PM
Abstract Number: 1278
Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
10:30AM-12:30PM
Abstract Number: 1461
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 1195
Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies
10:30AM-12:30PM
Abstract Number: 1505
Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
10:30AM-12:30PM
Abstract Number: 0926
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
10:30AM-12:30PM
Abstract Number: 1624
Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells
10:30AM-12:30PM
Abstract Number: 1551
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
10:30AM-12:30PM
Abstract Number: 1508
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
10:30AM-12:30PM
Abstract Number: 0898
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
10:30AM-12:30PM
Abstract Number: 1101
Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
10:30AM-12:30PM
Abstract Number: 0988
Distinct Effects of Inhibitory Receptor Agonism on RA Synovial CD4+ T Cell Functions
10:30AM-12:30PM
Abstract Number: 1184
Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.
10:30AM-12:30PM
Abstract Number: 1340
Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?
10:30AM-12:30PM
Abstract Number: 1649
Does Physical Activity Differ Among those with Autoimmune vs Non-Autoimmune Rheumatic Diseases?
10:30AM-12:30PM
Abstract Number: 1232
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 1302
Dose Adjustment was Necessary in Patients with Cryopyrin-Associated Periodic Syndrome Switching from Anakinra to Canakinumab
10:30AM-12:30PM
Abstract Number: 1269
Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions
10:30AM-12:30PM
Abstract Number: 1481
Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
10:30AM-10:45AM
Abstract Number: 0887
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
10:30AM-12:30PM
Abstract Number: 0908
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 1610
Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
10:30AM-12:30PM
Abstract Number: 1365
Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
10:30AM-12:30PM
Abstract Number: 1371
Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
10:30AM-12:30PM
Abstract Number: 1191
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
10:30AM-12:30PM
Abstract Number: 1460
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
10:30AM-12:30PM
Abstract Number: 1354
Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
10:30AM-12:30PM
Abstract Number: 1373
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
10:30AM-12:30PM
Abstract Number: 1164
Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
10:30AM-12:30PM
Abstract Number: 1463
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
10:30AM-12:30PM
Abstract Number: 1597
Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
10:30AM-12:30PM
Abstract Number: 1611
Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
10:30AM-12:30PM
Abstract Number: 1273
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1336
Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 1017
Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
10:30AM-12:30PM
Abstract Number: 1129
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
10:30AM-12:30PM
Abstract Number: 1419
Effectivenss of an educational program on non-radiographic axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0973
Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
10:30AM-12:30PM
Abstract Number: 1134
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1518
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
10:30AM-10:45AM
Abstract Number: 0875
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
10:30AM-12:30PM
Abstract Number: 1321
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
10:30AM-12:30PM
Abstract Number: 1245
Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
10:30AM-12:30PM
Abstract Number: 1179
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
10:30AM-12:30PM
Abstract Number: 1545
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
10:30AM-12:30PM
Abstract Number: 1441
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
10:30AM-12:30PM
Abstract Number: 1608
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
10:30AM-12:30PM
Abstract Number: 1364
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
10:30AM-12:30PM
Abstract Number: 1222
Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1323
Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 1138
Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
10:30AM-12:30PM
Abstract Number: 1361
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
10:30AM-12:30PM
Abstract Number: 1028
Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
10:30AM-12:30PM
Abstract Number: 0950
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
10:30AM-12:30PM
Abstract Number: 1583
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
10:30AM-12:30PM
Abstract Number: 0951
Epidermal IFNκ Increases Circulating and Cutaneous Monocytes in a C57/Bl6 Overexpression Mouse Model
10:30AM-12:30PM
Abstract Number: 1281
Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1360
Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
10:30AM-12:30PM
Abstract Number: 1617
Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
10:30AM-12:30PM
Abstract Number: 1536
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
10:30AM-12:30PM
Abstract Number: 1584
Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics
10:30AM-12:30PM
Abstract Number: 1482
Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
10:30AM-12:30PM
Abstract Number: 1363
Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
10:30AM-12:30PM
Abstract Number: 1115
Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
10:30AM-12:30PM
Abstract Number: 1483
Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
10:30AM-12:30PM
Abstract Number: 1312
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
10:30AM-12:30PM
Abstract Number: 1410
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
10:30AM-12:30PM
Abstract Number: 0980
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1344
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 0939
Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1579
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 1032
Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
10:30AM-12:30PM
Abstract Number: 1229
Extent versus impact: Sex-specific burden of chronic pain in older adults
10:30AM-12:30PM
Abstract Number: 1625
Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
10:30AM-12:30PM
Abstract Number: 1014
Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
10:30AM-12:30PM
Abstract Number: 1036
Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
10:30AM-12:30PM
Abstract Number: 1018
Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
10:30AM-12:30PM
Abstract Number: 1566
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1106
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
10:30AM-12:30PM
Abstract Number: 1491
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
10:30AM-12:30PM
Abstract Number: 0921
Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
10:30AM-12:30PM
Abstract Number: 1462
Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
10:30AM-12:30PM
Abstract Number: 1275
Fostering connections in Pediatric Rheumatology: A Narrative medicine intervention
10:30AM-12:30PM
Abstract Number: 0969
FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?
10:30AM-12:30PM
Abstract Number: 0992
FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
10:30AM-12:30PM
Abstract Number: 0920
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
10:30AM-12:30PM
Abstract Number: 1459
Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
10:30AM-12:30PM
Abstract Number: 1558
Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study
10:30AM-12:30PM
Abstract Number: 1291
Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
10:30AM-12:30PM
Abstract Number: 1180
Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
10:30AM-12:30PM
Abstract Number: 1063
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
10:30AM-12:30PM
Abstract Number: 1423
Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
10:30AM-12:30PM
Abstract Number: 1523
Genetic architecture and translational insights for SLE progression from preclinical stages
10:30AM-12:30PM
Abstract Number: 1197
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
10:30AM-12:30PM
Abstract Number: 0970
Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis
10:30AM-12:30PM
Abstract Number: 1027
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
10:30AM-12:30PM
Abstract Number: 0981
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1143
Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
10:30AM-12:30PM
Abstract Number: 1596
GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
10:30AM-12:30PM
Abstract Number: 1526
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
10:30AM-12:30PM
Abstract Number: 1077
Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
10:30AM-12:30PM
Abstract Number: 1263
Health Literacy diversity among rheumatology patients: insights from a tertiary rheumatology centre
10:30AM-12:30PM
Abstract Number: 1573
Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
10:30AM-12:30PM
Abstract Number: 1034
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1056
High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
10:30AM-12:30PM
Abstract Number: 1202
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
10:30AM-12:30PM
Abstract Number: 1174
High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
10:30AM-12:30PM
Abstract Number: 1504
High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
10:30AM-12:30PM
Abstract Number: 1322
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
10:30AM-12:30PM
Abstract Number: 1315
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1404
Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement
10:30AM-12:30PM
Abstract Number: 1083
How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
10:30AM-12:30PM
Abstract Number: 0989
Human MAIT cell produce IL-17 independently of IL-23 and TL1A
10:30AM-12:30PM
Abstract Number: 0924
Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
10:30AM-12:30PM
Abstract Number: 1377
Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life
10:30AM-12:30PM
Abstract Number: 1475
Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1570
Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
10:30AM-12:30PM
Abstract Number: 1524
Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0903
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
10:30AM-12:30PM
Abstract Number: 0997
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
10:30AM-12:30PM
Abstract Number: 1433
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
10:30AM-12:30PM
Abstract Number: 1298
Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
10:30AM-12:30PM
Abstract Number: 1192
Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
10:30AM-12:30PM
Abstract Number: 1190
IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort
10:30AM-12:30PM
Abstract Number: 0978
IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
10:30AM-12:30PM
Abstract Number: 1159
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
10:30AM-12:30PM
Abstract Number: 0979
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
10:30AM-12:30PM
Abstract Number: 1113
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
10:30AM-12:30PM
Abstract Number: 1104
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
10:30AM-12:30PM
Abstract Number: 1604
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
10:30AM-12:30PM
Abstract Number: 1466
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
10:30AM-12:30PM
Abstract Number: 1427
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1040
Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 1576
Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
10:30AM-12:30PM
Abstract Number: 1303
Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
10:30AM-12:30PM
Abstract Number: 1283
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1048
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
10:30AM-12:30PM
Abstract Number: 1150
Impact of IL-17A on synovial fibroblast from subacromial bursae
10:30AM-12:30PM
Abstract Number: 1096
Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
10:30AM-12:30PM
Abstract Number: 0982
Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
10:30AM-12:30PM
Abstract Number: 1489
Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1087
Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1421
Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
10:30AM-12:30PM
Abstract Number: 1369
Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy: A Retrospective Study
10:30AM-12:30PM
Abstract Number: 1370
Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
10:30AM-12:30PM
Abstract Number: 1435
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
10:30AM-12:30PM
Abstract Number: 1418
Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
10:30AM-12:30PM
Abstract Number: 1294
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
10:30AM-12:30PM
Abstract Number: 0927
Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
10:30AM-12:30PM
Abstract Number: 1549
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
10:30AM-12:30PM
Abstract Number: 0941
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1535
INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1156
Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort
10:30AM-12:30PM
Abstract Number: 1464
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
10:30AM-12:30PM
Abstract Number: 1072
Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review
10:30AM-12:30PM
Abstract Number: 1186
Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
10:30AM-12:30PM
Abstract Number: 0963
Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
10:30AM-12:30PM
Abstract Number: 1118
Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
10:30AM-12:30PM
Abstract Number: 1137
Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1270
Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study
10:30AM-12:30PM
Abstract Number: 1260
Increasing Zoster Vaccination Rates in Immunosuppressed Veterans at the North Texas VA Medical Center Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 1198
Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
10:30AM-12:30PM
Abstract Number: 1117
Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
10:30AM-12:30PM
Abstract Number: 1339
Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
10:30AM-12:30PM
Abstract Number: 1396
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1528
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1448
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
10:30AM-12:30PM
Abstract Number: 0923
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
10:30AM-12:30PM
Abstract Number: 0965
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1350
Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
10:30AM-12:30PM
Abstract Number: 1081
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
10:30AM-12:30PM
Abstract Number: 1257
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
10:30AM-12:30PM
Abstract Number: 0966
Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
10:30AM-12:30PM
Abstract Number: 0984
Interleukin-21 as a driver of CD8 T cell tissue resident memory and pathogenesis in dermatomyositis
10:30AM-12:30PM
Abstract Number: 1300
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
10:30AM-12:30PM
Abstract Number: 1148
Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center
10:30AM-12:30PM
Abstract Number: 1382
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
10:30AM-12:30PM
Abstract Number: 1199
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
10:30AM-12:30PM
Abstract Number: 1168
Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
10:30AM-12:30PM
Abstract Number: 1577
Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
10:30AM-12:30PM
Abstract Number: 1067
Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
10:30AM-12:30PM
Abstract Number: 1280
Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
10:30AM-12:30PM
Abstract Number: 1285
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
10:30AM-12:30PM
Abstract Number: 1288
Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
10:30AM-12:30PM
Abstract Number: 1239
JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study
10:30AM-12:30PM
Abstract Number: 1521
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
10:30AM-12:30PM
Abstract Number: 0944
L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis
10:30AM-12:30PM
Abstract Number: 1121
Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
10:30AM-12:30PM
Abstract Number: 1556
Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
10:30AM-12:30PM
Abstract Number: 0986
LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders.
10:30AM-12:30PM
Abstract Number: 1001
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
10:30AM-12:30PM
Abstract Number: 1086
Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records
10:30AM-12:30PM
Abstract Number: 1057
Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
10:30AM-12:30PM
Abstract Number: 1488
Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 0975
Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
10:30AM-12:30PM
Abstract Number: 1296
Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
10:30AM-12:30PM
Abstract Number: 0976
LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
10:30AM-12:30PM
Abstract Number: 1537
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 1520
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1447
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
10:30AM-12:30PM
Abstract Number: 1493
Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
10:30AM-12:30PM
Abstract Number: 1432
Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
10:30AM-12:30PM
Abstract Number: 1443
Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
10:30AM-12:30PM
Abstract Number: 1454
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 1456
Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
10:30AM-12:30PM
Abstract Number: 1560
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
10:30AM-12:30PM
Abstract Number: 1587
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
10:30AM-12:30PM
Abstract Number: 1289
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
10:30AM-12:30PM
Abstract Number: 0959
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
10:30AM-12:30PM
Abstract Number: 1644
Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0909
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
10:30AM-12:30PM
Abstract Number: 1543
Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
10:30AM-12:30PM
Abstract Number: 1193
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
10:30AM-12:30PM
Abstract Number: 1255
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
10:30AM-12:30PM
Abstract Number: 1580
Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1503
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
10:30AM-12:30PM
Abstract Number: 1527
Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
10:30AM-12:30PM
Abstract Number: 1082
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
10:30AM-12:30PM
Abstract Number: 0985
Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
10:30AM-12:30PM
Abstract Number: 1485
Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index
10:30AM-12:30PM
Abstract Number: 1515
Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
10:30AM-12:30PM
Abstract Number: 1424
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0956
Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics
10:30AM-12:30PM
Abstract Number: 1216
Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 1357
Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
10:30AM-12:30PM
Abstract Number: 0947
Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
10:30AM-12:30PM
Abstract Number: 1511
Mental Health and Medical Burden:  The Impact of Depression on Length of Stay in Lupus Patients
10:30AM-12:30PM
Abstract Number: 1276
Mental Health Screening Implementation for Pediatric Rheumatology Patients at a Tertiary Academic Medical Center
10:30AM-12:30PM
Abstract Number: 1592
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
10:30AM-12:30PM
Abstract Number: 0968
Mesenchymal Stromal Cells in Systemic Sclerosis are Dysfunctional and Have a Profibrotic and Senescent Phenotype
10:30AM-12:30PM
Abstract Number: 1119
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
10:30AM-12:30PM
Abstract Number: 1332
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1051
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
10:30AM-12:30PM
Abstract Number: 1011
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
10:30AM-12:30PM
Abstract Number: 1141
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
10:30AM-12:30PM
Abstract Number: 1442
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1367
Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 1200
Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)
10:30AM-12:30PM
Abstract Number: 1024
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
10:30AM-12:30PM
Abstract Number: 1328
Mortality Trends of Hypertension in Patients with Rheumatoid Arthritis in the United States (1999–2020)
10:30AM-12:30PM
Abstract Number: 0937
MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
10:30AM-12:30PM
Abstract Number: 0991
MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 0957
Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
10:30AM-12:30PM
Abstract Number: 1114
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
10:30AM-12:30PM
Abstract Number: 1414
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
10:30AM-12:30PM
Abstract Number: 1362
Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
10:30AM-10:45AM
Abstract Number: 0863
Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
10:30AM-12:30PM
Abstract Number: 1246
Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 0999
Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells
10:30AM-12:30PM
Abstract Number: 1187
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1123
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
10:30AM-12:30PM
Abstract Number: 1008
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
10:30AM-12:30PM
Abstract Number: 1310
Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record
10:30AM-12:30PM
Abstract Number: 0945
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
10:30AM-12:30PM
Abstract Number: 1295
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
10:30AM-12:30PM
Abstract Number: 1208
Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
10:30AM-12:30PM
Abstract Number: 1631
New Arterial Damage in Takayasu’s Arteritis
10:30AM-12:30PM
Abstract Number: 1153
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
10:30AM-12:30PM
Abstract Number: 1589
Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
10:30AM-12:30PM
Abstract Number: 0953
NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
10:30AM-12:30PM
Abstract Number: 0993
NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
10:30AM-12:30PM
Abstract Number: 1130
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
10:30AM-12:30PM
Abstract Number: 1591
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
10:30AM-12:30PM
Abstract Number: 1145
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
10:30AM-12:30PM
Abstract Number: 1383
Obesity in Primary Sjogren’s Disease
10:30AM-12:30PM
Abstract Number: 1601
Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
10:30AM-12:30PM
Abstract Number: 1606
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
10:30AM-12:30PM
Abstract Number: 1643
Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
10:30AM-12:30PM
Abstract Number: 0935
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1509
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
10:30AM-12:30PM
Abstract Number: 1522
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
10:30AM-12:30PM
Abstract Number: 1271
Overcoming Obstacles to Care: Survey of Adult Patients with Idiopathic Inflammatory Myopathies (IIM)
10:30AM-12:30PM
Abstract Number: 1206
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
10:30AM-12:30PM
Abstract Number: 1221
Oxytocin pathway gene BST1 polymorphism rs4273468 genotype GG is negatively associated with Fibromyalgia
10:30AM-12:30PM
Abstract Number: 1244
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
10:30AM-12:30PM
Abstract Number: 1223
Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
10:30AM-12:30PM
Abstract Number: 1238
Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0925
Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1259
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
10:30AM-12:30PM
Abstract Number: 1248
Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 1445
Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
10:30AM-12:30PM
Abstract Number: 1250
Patient Perceptions of the National Tele-Rheumatology Program: A Mixed Methods Study
10:30AM-12:30PM
Abstract Number: 1265
Patient Portal Awareness and Utilization Across Diverse Rheumatology Populations
10:30AM-12:30PM
Abstract Number: 1253
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
10:30AM-12:30PM
Abstract Number: 1267
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
10:30AM-12:30PM
Abstract Number: 1149
Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
10:30AM-10:45AM
Abstract Number: 0869
PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice
10:30AM-12:30PM
Abstract Number: 1299
Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
10:30AM-12:30PM
Abstract Number: 1169
Periodontitis in neutropenic DADA2 patients
10:30AM-12:30PM
Abstract Number: 1446
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
10:30AM-12:30PM
Abstract Number: 1262
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
10:30AM-12:30PM
Abstract Number: 1506
Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
10:30AM-12:30PM
Abstract Number: 1632
PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteritis
10:30AM-12:30PM
Abstract Number: 1140
PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
10:30AM-12:30PM
Abstract Number: 0960
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1353
Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
10:30AM-12:30PM
Abstract Number: 0922
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
10:30AM-12:30PM
Abstract Number: 1380
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
10:30AM-12:30PM
Abstract Number: 1341
Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
10:30AM-12:30PM
Abstract Number: 1640
Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts
10:30AM-12:30PM
Abstract Number: 1160
Plasma Adenosine Deaminase 2 as a Potential Disease Activity Biomarker for Sarcoidosis
10:30AM-12:30PM
Abstract Number: 1211
Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
10:30AM-12:30PM
Abstract Number: 1307
Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)
10:30AM-12:30PM
Abstract Number: 1325
Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1097
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
10:30AM-12:30PM
Abstract Number: 1388
Positive predictive value of various diagnostic codes for the classification of primary Sjӧgren’s syndrome
10:30AM-12:30PM
Abstract Number: 1519
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
10:30AM-12:30PM
Abstract Number: 0930
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0913
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
10:30AM-12:30PM
Abstract Number: 1003
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology 
10:30AM-12:30PM
Abstract Number: 0998
Preclinical Characterization of a Novel Bi-specific Antibody Targeting IL-23p19 and IL-36R for The Treatment of Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 0906
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 0914
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
10:30AM-12:30PM
Abstract Number: 1316
Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study
10:30AM-12:30PM
Abstract Number: 1648
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
10:30AM-12:30PM
Abstract Number: 1352
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
10:30AM-12:30PM
Abstract Number: 1030
Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study
10:30AM-12:30PM
Abstract Number: 1308
Predictors of Interstitial Lung Disease Progression in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1220
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
10:30AM-12:30PM
Abstract Number: 1499
Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1009
Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
10:30AM-12:30PM
Abstract Number: 1177
Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study
10:30AM-12:30PM
Abstract Number: 1226
Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome
10:30AM-12:30PM
Abstract Number: 1346
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
10:30AM-12:30PM
Abstract Number: 1532
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 0948
Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease
10:30AM-12:30PM
Abstract Number: 1502
Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1471
Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
10:30AM-12:30PM
Abstract Number: 1492
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1196
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 1378
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1615
Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1173
Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
10:30AM-12:30PM
Abstract Number: 1058
Prevalence of Depression Associated with Rheumatologic Medications with Labeled Warnings: Real World Evidence from a Tertiary Care Center
10:30AM-12:30PM
Abstract Number: 1588
Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study
10:30AM-12:30PM
Abstract Number: 1555
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
10:30AM-12:30PM
Abstract Number: 1393
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
10:30AM-12:30PM
Abstract Number: 1301
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1047
Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
10:30AM-12:30PM
Abstract Number: 1092
Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
10:30AM-12:30PM
Abstract Number: 0900
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 1500
Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
10:30AM-12:30PM
Abstract Number: 1201
Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 0972
Prominent endothelial senescence in systemic sclerosis skin
10:30AM-12:30PM
Abstract Number: 1314
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 0919
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
10:30AM-12:30PM
Abstract Number: 1049
Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1185
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
10:30AM-12:30PM
Abstract Number: 1425
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
10:30AM-12:30PM
Abstract Number: 1256
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1090
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1513
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
10:30AM-12:30PM
Abstract Number: 1012
Racial and Gender Disparities in Gout Clinical Trials
10:30AM-12:30PM
Abstract Number: 1075
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
10:30AM-12:30PM
Abstract Number: 1076
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
10:30AM-12:30PM
Abstract Number: 1074
Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
10:30AM-12:30PM
Abstract Number: 1431
Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
10:30AM-12:30PM
Abstract Number: 0928
Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
10:30AM-12:30PM
Abstract Number: 1534
Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
10:30AM-12:30PM
Abstract Number: 1348
Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
10:30AM-12:30PM
Abstract Number: 1401
Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
10:30AM-12:30PM
Abstract Number: 1205
Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
10:30AM-12:30PM
Abstract Number: 1600
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
10:30AM-12:30PM
Abstract Number: 1444
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1453
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
10:30AM-12:30PM
Abstract Number: 1629
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
10:30AM-12:30PM
Abstract Number: 1358
Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
10:30AM-12:30PM
Abstract Number: 1038
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
10:30AM-12:30PM
Abstract Number: 1165
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
10:30AM-12:30PM
Abstract Number: 1550
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
10:30AM-12:30PM
Abstract Number: 1457
Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
10:30AM-12:30PM
Abstract Number: 1586
Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
10:30AM-12:30PM
Abstract Number: 1282
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
10:30AM-12:30PM
Abstract Number: 1021
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1430
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
10:30AM-12:30PM
Abstract Number: 0931
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
10:30AM-12:30PM
Abstract Number: 1015
Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
10:30AM-12:30PM
Abstract Number: 1212
Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
10:30AM-12:30PM
Abstract Number: 1247
Relation of Measures of Pain Sensitization to Widespread Pain
10:30AM-12:30PM
Abstract Number: 1329
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1242
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
10:30AM-12:30PM
Abstract Number: 1215
Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort
10:30AM-12:30PM
Abstract Number: 1469
Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1147
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
10:30AM-12:30PM
Abstract Number: 1379
Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
10:30AM-12:30PM
Abstract Number: 1398
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
10:30AM-12:30PM
Abstract Number: 1563
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0940
Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling
10:30AM-12:30PM
Abstract Number: 0995
Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes
10:30AM-12:30PM
Abstract Number: 1286
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1413
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
10:30AM-12:30PM
Abstract Number: 0918
Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
10:30AM-12:30PM
Abstract Number: 1033
Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
10:30AM-12:30PM
Abstract Number: 1474
Rethinking Heart Risk Prediction for Lupus Patients
10:30AM-12:30PM
Abstract Number: 0961
Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
10:30AM-12:30PM
Abstract Number: 1313
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
10:30AM-12:30PM
Abstract Number: 1037
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1467
Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1582
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
10:30AM-12:30PM
Abstract Number: 1194
Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1183
Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
10:30AM-12:30PM
Abstract Number: 1093
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1203
Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
10:30AM-12:30PM
Abstract Number: 1525
Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
10:30AM-12:30PM
Abstract Number: 0987
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
10:30AM-12:30PM
Abstract Number: 1099
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
10:30AM-12:30PM
Abstract Number: 1157
Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
10:30AM-12:30PM
Abstract Number: 1434
Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
10:30AM-12:30PM
Abstract Number: 1091
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
10:30AM-12:30PM
Abstract Number: 1538
Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
10:30AM-12:30PM
Abstract Number: 1061
Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
10:30AM-12:30PM
Abstract Number: 1026
Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
10:30AM-12:30PM
Abstract Number: 1116
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
10:30AM-12:30PM
Abstract Number: 1175
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
10:30AM-12:30PM
Abstract Number: 1381
Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
10:30AM-12:30PM
Abstract Number: 1234
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
10:30AM-12:30PM
Abstract Number: 1514
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1240
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
10:30AM-12:30PM
Abstract Number: 1330
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
10:30AM-12:30PM
Abstract Number: 1062
Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
10:30AM-12:30PM
Abstract Number: 1603
SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
10:30AM-12:30PM
Abstract Number: 1266
Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
10:30AM-12:30PM
Abstract Number: 0938
Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
10:30AM-12:30PM
Abstract Number: 1338
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
10:30AM-12:30PM
Abstract Number: 1616
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
10:30AM-12:30PM
Abstract Number: 1399
Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease
10:30AM-12:30PM
Abstract Number: 1438
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
10:30AM-12:30PM
Abstract Number: 1324
Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study
10:30AM-12:30PM
Abstract Number: 1004
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
10:30AM-12:30PM
Abstract Number: 0967
Single-Cell RNA Sequencing Reveals a Prominent Pro-Inflammatory Gene Signature of Dermal Fibroblasts in Pre-Stages of SSc
10:30AM-12:30PM
Abstract Number: 1237
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
10:30AM-12:30PM
Abstract Number: 1343
Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
10:30AM-12:30PM
Abstract Number: 0904
SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
10:30AM-12:30PM
Abstract Number: 1637
Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 1633
Social Determinants of Health and Adverse Perinatal Outcomes in Women with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1218
Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
10:30AM-12:30PM
Abstract Number: 1079
Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 0942
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
10:30AM-12:30PM
Abstract Number: 1455
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
10:30AM-12:30PM
Abstract Number: 0929
SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
10:30AM-12:30PM
Abstract Number: 0962
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
10:30AM-12:30PM
Abstract Number: 1571
Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
10:30AM-12:30PM
Abstract Number: 0933
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
10:30AM-12:30PM
Abstract Number: 1251
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
10:30AM-12:30PM
Abstract Number: 1069
Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
10:30AM-12:30PM
Abstract Number: 1416
Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
10:30AM-12:30PM
Abstract Number: 1595
Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
10:30AM-12:30PM
Abstract Number: 0955
Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis
10:30AM-12:30PM
Abstract Number: 1429
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
10:30AM-12:30PM
Abstract Number: 1465
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
10:30AM-12:30PM
Abstract Number: 1613
Switching From Reference Tocilizumab to Biosimilar in Giant Cell Arteritis: Effectiveness and Safety in a Multicenter Study of 38 Patients
10:30AM-12:30PM
Abstract Number: 1254
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
10:30AM-12:30PM
Abstract Number: 1120
Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
10:30AM-12:30PM
Abstract Number: 1139
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
10:30AM-12:30PM
Abstract Number: 1233
Synovial Joint Transcriptomic Differences in Individuals with Knee Osteoarthritis and Neuropathic Pain Symptomology
10:30AM-12:30PM
Abstract Number: 0917
Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1293
Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study
10:30AM-12:30PM
Abstract Number: 1306
Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1327
Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment
10:30AM-12:30PM
Abstract Number: 1384
Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1619
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
10:30AM-12:30PM
Abstract Number: 1486
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
10:30AM-12:30PM
Abstract Number: 1546
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
10:30AM-12:30PM
Abstract Number: 1621
Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center
10:30AM-12:30PM
Abstract Number: 1507
Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
10:30AM-12:30PM
Abstract Number: 1337
The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
10:30AM-12:30PM
Abstract Number: 1317
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
10:30AM-12:30PM
Abstract Number: 1623
The Association of Calprotectin with Vascular Injury and Remodeling in Clinically-Isolated Aortitis
10:30AM-12:30PM
Abstract Number: 1415
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 1319
The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1516
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
10:30AM-12:30PM
Abstract Number: 1347
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 0949
The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
10:30AM-12:30PM
Abstract Number: 1043
The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
10:30AM-12:30PM
Abstract Number: 1517
The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
10:30AM-12:30PM
Abstract Number: 1227
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1342
The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
10:30AM-12:30PM
Abstract Number: 1636
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
10:30AM-12:30PM
Abstract Number: 1409
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
10:30AM-12:30PM
Abstract Number: 1539
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
10:30AM-12:30PM
Abstract Number: 1136
The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
10:30AM-12:30PM
Abstract Number: 1642
The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
10:30AM-12:30PM
Abstract Number: 1450
The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
10:30AM-12:30PM
Abstract Number: 0977
The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1646
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
10:30AM-12:30PM
Abstract Number: 1581
The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
10:30AM-12:30PM
Abstract Number: 1127
The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
10:30AM-12:30PM
Abstract Number: 1055
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
10:30AM-12:30PM
Abstract Number: 1530
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1304
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
10:30AM-12:30PM
Abstract Number: 0934
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
10:30AM-12:30PM
Abstract Number: 0952
Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus
10:30AM-12:30PM
Abstract Number: 1501
Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data
10:30AM-12:30PM
Abstract Number: 1368
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
10:30AM-12:30PM
Abstract Number: 1142
Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD
10:30AM-12:30PM
Abstract Number: 0974
Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1231
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
10:30AM-12:30PM
Abstract Number: 1541
Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
10:30AM-12:30PM
Abstract Number: 1098
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
10:30AM-12:30PM
Abstract Number: 1095
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
10:30AM-12:30PM
Abstract Number: 1228
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
10:30AM-12:30PM
Abstract Number: 1309
Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis
10:30AM-10:45AM
Abstract Number: 0893
Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
10:30AM-12:30PM
Abstract Number: 1213
Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
10:30AM-12:30PM
Abstract Number: 1403
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
10:30AM-12:30PM
Abstract Number: 1372
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
10:30AM-12:30PM
Abstract Number: 1552
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
10:30AM-12:30PM
Abstract Number: 1031
Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
10:30AM-12:30PM
Abstract Number: 1053
Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)
10:30AM-12:30PM
Abstract Number: 1407
Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
10:30AM-12:30PM
Abstract Number: 1078
Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023
10:30AM-12:30PM
Abstract Number: 1320
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1110
Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
10:30AM-12:30PM
Abstract Number: 1594
Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
10:30AM-12:30PM
Abstract Number: 0943
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
10:30AM-12:30PM
Abstract Number: 0936
Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
10:30AM-12:30PM
Abstract Number: 1402
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1426
Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 0971
Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
10:30AM-12:30PM
Abstract Number: 1088
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
10:30AM-12:30PM
Abstract Number: 1258
Upadacitinib in the treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
10:30AM-12:30PM
Abstract Number: 1529
Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
10:30AM-12:30PM
Abstract Number: 1345
Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study
10:30AM-12:30PM
Abstract Number: 1480
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
10:30AM-12:30PM
Abstract Number: 1356
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
10:30AM-12:30PM
Abstract Number: 1598
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
10:30AM-12:30PM
Abstract Number: 1618
Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
10:30AM-12:30PM
Abstract Number: 1355
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
10:30AM-12:30PM
Abstract Number: 1261
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
10:30AM-12:30PM
Abstract Number: 1578
Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
10:30AM-12:30PM
Abstract Number: 1561
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
10:30AM-12:30PM
Abstract Number: 0994
UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 0916
UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway
10:30AM-12:30PM
Abstract Number: 1217
Validation and clincial use of anti-MDA5 test – LIA versus ELISA
10:30AM-12:30PM
Abstract Number: 1564
Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 1125
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
10:30AM-12:30PM
Abstract Number: 1479
Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
10:30AM-12:30PM
Abstract Number: 1630
Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
10:30AM-12:30PM
Abstract Number: 1103
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 1204
Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.
10:30AM-12:30PM
Abstract Number: 1131
Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
10:30AM-12:30PM
Abstract Number: 1562
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
10:30AM-12:30PM
Abstract Number: 1236
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
10:30AM-12:30PM
Abstract Number: 1171
VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy
10:30AM-12:30PM
Abstract Number: 1176
VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
10:30AM-12:30PM
Abstract Number: 1490
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
10:30AM-12:30PM
Abstract Number: 1544
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
10:30AM-12:30PM
Abstract Number: 1408
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
10:30AM-12:30PM
Abstract Number: 1279
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
10:30AM-12:30PM
Abstract Number: 1487
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
10:30AM-12:30PM
Abstract Number: 1470
Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
10:30AM-12:30PM
Abstract Number: 1612
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
10:30AM-12:30PM
Abstract Number: 1155
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
10:45AM-11:00AM
Abstract Number: 0894
Altered B cell subpopulations in Giant Cell Arteritis
10:45AM-11:00AM
Abstract Number: 0876
Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
10:45AM-11:00AM
Abstract Number: 0858
IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
10:45AM-11:00AM
Abstract Number: 0864
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
10:45AM-11:00AM
Abstract Number: 0870
Same Model, Different Results: Vendor and Microbiome Influence Reproducibility in Collagen Induced Arthritis
10:45AM-11:00AM
Abstract Number: 0882
Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
10:45AM-11:00AM
Abstract Number: 0888
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
11:00AM-11:15AM
Abstract Number: 0895
Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
11:00AM-11:15AM
Abstract Number: 0889
Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis
11:00AM-11:15AM
Abstract Number: 0883
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
11:00AM-11:15AM
Abstract Number: 0865
Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
11:00AM-11:15AM
Abstract Number: 0871
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
11:00AM-11:15AM
Abstract Number: 0877
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
11:00AM-11:15AM
Abstract Number: 0859
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
11:15AM-11:30AM
Abstract Number: 0860
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
11:15AM-11:30AM
Abstract Number: 0896
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
11:15AM-11:30AM
Abstract Number: 0878
Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
11:15AM-11:30AM
Abstract Number: 0890
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
11:15AM-11:30AM
Abstract Number: 0866
Immunoglobulin from sera of patients with myositis can passively enter cultured human endothelial cells
11:15AM-11:30AM
Abstract Number: 0884
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
11:15AM-11:30AM
Abstract Number: 0872
Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.
1:00PM-1:15PM
Abstract Number: 1668
A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases
1:00PM-1:15PM
Abstract Number: 1674
A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
1:00PM-1:15PM
Abstract Number: 1662
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
1:00PM-1:15PM
Abstract Number: 1680
Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
1:00PM-1:15PM
Abstract Number: 1650
Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
1:00PM-1:15PM
Abstract Number: 1656
Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
1:15PM-1:30PM
Abstract Number: 1651
Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations
1:15PM-1:30PM
Abstract Number: 1669
Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
1:15PM-1:30PM
Abstract Number: 1657
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
1:15PM-1:30PM
Abstract Number: 1681
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
1:15PM-1:30PM
Abstract Number: 1675
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
1:15PM-1:30PM
Abstract Number: 1663
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
1:30PM-1:45PM
Abstract Number: 1664
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
1:30PM-1:45PM
Abstract Number: 1658
Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
1:30PM-1:45PM
Abstract Number: 1670
Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
1:30PM-1:45PM
Abstract Number: 1676
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
1:30PM-1:45PM
Abstract Number: 1682
Sjögren’s Disease Salivary Gland Fibroblast Subsets are Proinflammatory and Aberrantly Promote Pain
1:30PM-1:45PM
Abstract Number: 1652
The Hidden Impact of Hyperuricemia on Immune Cell Dysfunction
1:45PM-2:00PM
Abstract Number: 1665
Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
1:45PM-2:00PM
Abstract Number: 1671
Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
1:45PM-2:00PM
Abstract Number: 1677
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
1:45PM-2:00PM
Abstract Number: 1653
Gut-joint lymphocyte trafficking functions to regulate systemic immunity
1:45PM-2:00PM
Abstract Number: 1659
Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
1:45PM-2:00PM
Abstract Number: 1683
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
2:00PM-2:15PM
Abstract Number: 1654
A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
2:00PM-2:15PM
Abstract Number: 1678
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
2:00PM-2:15PM
Abstract Number: 1672
Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood
2:00PM-2:15PM
Abstract Number: 1660
Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial
2:00PM-2:15PM
Abstract Number: 1684
Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus
2:00PM-2:15PM
Abstract Number: 1666
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
2:15PM-2:30PM
Abstract Number: 1655
Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
2:15PM-2:30PM
Abstract Number: 1661
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
2:15PM-2:30PM
Abstract Number: 1679
Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
2:15PM-2:30PM
Abstract Number: 1673
Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
2:15PM-2:30PM
Abstract Number: 1667
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
2:15PM-2:30PM
Abstract Number: 1685
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
3:00PM-3:15PM
Abstract Number: 1710
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
3:00PM-3:15PM
Abstract Number: 1704
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
3:00PM-3:15PM
Abstract Number: 1692
Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis
3:00PM-3:15PM
Abstract Number: 1716
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
3:00PM-3:15PM
Abstract Number: 1686
The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
3:00PM-3:15PM
Abstract Number: 1698
X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
3:15PM-3:30PM
Abstract Number: 1705
Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions
3:15PM-3:30PM
Abstract Number: 1687
Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
3:15PM-3:30PM
Abstract Number: 1693
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
3:15PM-3:30PM
Abstract Number: 1711
Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis
3:15PM-3:30PM
Abstract Number: 1699
Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus
3:15PM-3:30PM
Abstract Number: 1717
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
3:30PM-3:45PM
Abstract Number: 1700
Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions
3:30PM-3:45PM
Abstract Number: 1688
Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients
3:30PM-3:45PM
Abstract Number: 1718
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
3:30PM-3:45PM
Abstract Number: 1694
Obesity Exacerbates Autoimmunity by Dysregulating B Cell Behavior
3:30PM-3:45PM
Abstract Number: 1706
Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
3:30PM-3:45PM
Abstract Number: 1712
Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
3:45PM-4:00PM
Abstract Number: 1689
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
3:45PM-4:00PM
Abstract Number: 1713
Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
3:45PM-4:00PM
Abstract Number: 1701
Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
3:45PM-4:00PM
Abstract Number: 1719
Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
3:45PM-4:00PM
Abstract Number: 1707
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
3:45PM-4:00PM
Abstract Number: 1695
The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
4:00PM-4:15PM
Abstract Number: 1696
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
4:00PM-4:15PM
Abstract Number: 1708
Assessing Social Determinants of Health Using PRAPARE in a Rheumatology Patient Navigator Program for Underserved Brooklyn Communities
4:00PM-4:15PM
Abstract Number: 1720
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
4:00PM-4:15PM
Abstract Number: 1690
Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus
4:00PM-4:15PM
Abstract Number: 1702
Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease
4:00PM-4:15PM
Abstract Number: 1714
The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
4:15PM-4:30PM
Abstract Number: 1709
Association Between Social Risk Factors and Major Adverse Cardiovascular Events Among Individuals with Rheumatic Conditions
4:15PM-4:30PM
Abstract Number: 1697
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
4:15PM-4:30PM
Abstract Number: 1721
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
4:15PM-4:30PM
Abstract Number: 1703
Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging
4:15PM-4:30PM
Abstract Number: 1715
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
4:15PM-4:30PM
Abstract Number: 1691
Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
8:00AM-8:15AM
Abstract Number: 1722
Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
8:15AM-8:30AM
Abstract Number: 1723
Impaired Maintenance of X-Chromosome Inactivation in B Cells, But Not T Cells, Exacerbates Interferon-Driven Systemic Autoimmunity
8:15AM-8:30AM
Abstract Number: PP09
The Role of a Palliative Care Support Team to Optimize Outcomes for Patients with Airway Involvement from Relapsing Polychondritis
8:30AM-8:45AM
Abstract Number: PP10
Breaking Through Scleroderma’s Invisible Struggles: From Isolation to Connection
8:30AM-8:45AM
Abstract Number: 1724
Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
8:45AM-9:00AM
Abstract Number: 1725
Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
8:45AM-9:00AM
Abstract Number: PP11
Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate
9:00AM-9:15AM
Abstract Number: PP12
From Invisibility to Advocacy: A Gout Patient’s Journey to Validation and Systemic Change
9:00AM-9:15AM
Abstract Number: 1726
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
9:15AM-9:30AM
Abstract Number: 1727
Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
9:15AM-9:30AM
Abstract Number: PP13
Life Transitions and Their Impact on Patients
10:00AM-10:15AM
Abstract Number: 1740
A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
10:00AM-10:15AM
Abstract Number: 1764
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
10:00AM-10:15AM
Abstract Number: 1746
Inflammatory- and Fibrosis-Related Biomarkers and Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
10:00AM-10:15AM
Abstract Number: 1734
Intra‑articular Liraglutide Halts Osteoarthritis Progression, Surpassing Dexamethasone in Synovial and Cartilage Protection
10:00AM-10:15AM
Abstract Number: 1728
Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
10:00AM-10:15AM
Abstract Number: 1752
Prg4+ Ligament Cells Are Involved in Ligament Ossification in Ankylosing Spondylitis
10:00AM-10:15AM
Abstract Number: 1758
Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
10:15AM-10:30AM
Abstract Number: 1753
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
10:15AM-10:30AM
Abstract Number: 1741
Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
10:15AM-10:30AM
Abstract Number: 1735
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
10:15AM-10:30AM
Abstract Number: 1765
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
10:15AM-10:30AM
Abstract Number: 1747
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
10:15AM-10:30AM
Abstract Number: 1759
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
10:15AM-10:30AM
Abstract Number: 1729
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
10:30AM-12:30PM
Abstract Number: 1956
68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study
10:30AM-12:30PM
Abstract Number: 2054
A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
10:30AM-12:30PM
Abstract Number: 2389
A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 2519
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
10:30AM-12:30PM
Abstract Number: 1936
A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH cohort
10:30AM-12:30PM
Abstract Number: 2396
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
10:30AM-12:30PM
Abstract Number: 2337
A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 1869
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
10:30AM-12:30PM
Abstract Number: 2204
A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications
10:30AM-12:30PM
Abstract Number: 2155
A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency
10:30AM-12:30PM
Abstract Number: 2011
A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
10:30AM-12:30PM
Abstract Number: 2012
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
10:30AM-12:30PM
Abstract Number: 2181
A Pilot High-Fidelity Simulation for Pediatric Rheumatology Learners
10:30AM-12:30PM
Abstract Number: 2247
A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array
10:30AM-12:30PM
Abstract Number: 2371
A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2053
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
10:30AM-12:30PM
Abstract Number: 1923
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
10:30AM-12:30PM
Abstract Number: 2177
A Rheumatologic Ultrasound (RhUS) Educational Framework: Expert Consensus on RhUS Skills for Adult Rheumatology Fellows in the United States
10:30AM-12:30PM
Abstract Number: 2542
A Rule Based NLP Pipeline for Glucocorticoid exposure
10:30AM-12:30PM
Abstract Number: 2494
Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1861
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 2445
Achievement of Treat to Target Measures With Upadacitinib in Patients With Systemic Lupus Erythematosus: Phase 2 Randomized SLEek Clinical Trial Results
10:30AM-12:30PM
Abstract Number: 2270
ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
10:30AM-12:30PM
Abstract Number: 2245
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
10:30AM-12:30PM
Abstract Number: 2176
Addressing Hesitancy in JAK Inhibitor Use: Outcomes from Continuing Medical Education Reveal Confidence-Knowledge Gaps Among Community Rheumatologists
10:30AM-12:30PM
Abstract Number: 1916
Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2201
Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
10:30AM-12:30PM
Abstract Number: LB07
Adipose-Tissue Derived Mesenchymal Stem Cells vs Hyaluronic Acid in Refractory Knee Osteoarthritis in a low-resource setting: A Phase IIb RCT
10:30AM-12:30PM
Abstract Number: 2206
Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
10:30AM-12:30PM
Abstract Number: 1988
Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
10:30AM-12:30PM
Abstract Number: LB06
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
10:30AM-12:30PM
Abstract Number: 2088
Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020
10:30AM-12:30PM
Abstract Number: 2275
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
10:30AM-12:30PM
Abstract Number: 2463
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 2315
Alterations in the gut microbiome in ankylosing spondylitis and their correlation with disease activity
10:30AM-12:30PM
Abstract Number: 1942
An Agnostic Evaluation of Serum Proteins Discriminates the Severity of Ultrasound Arthritis in SLE Patients
10:30AM-12:30PM
Abstract Number: 2564
An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
10:30AM-12:30PM
Abstract Number: 2162
An Updated Needs Assessment for the Virtual Rheumatology Program for Fellows in Training (V-FIT)
10:30AM-12:30PM
Abstract Number: 2242
Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 2395
Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1934
Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-Methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
10:30AM-12:30PM
Abstract Number: 2397
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
10:30AM-12:30PM
Abstract Number: 2398
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
10:30AM-12:30PM
Abstract Number: 2120
Analyzing Gender and Racial Disparities in Paget’s Disease of Bone: A Large-Scale Observational Study
10:30AM-12:30PM
Abstract Number: LB04
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 2417
Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
10:30AM-12:30PM
Abstract Number: 2386
Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
10:30AM-12:30PM
Abstract Number: 1858
Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.
10:30AM-12:30PM
Abstract Number: 2391
Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
10:30AM-12:30PM
Abstract Number: 2283
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
10:30AM-12:30PM
Abstract Number: 2565
Assessing Participation in the Lupus Sister Circle Support Group
10:30AM-12:30PM
Abstract Number: 1898
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
10:30AM-12:30PM
Abstract Number: 1966
Assessing the Impact of Cutaneous Melanin on Microvascular Oxygenation Measurement in Systemic Sclerosis Using Multispectral Imaging
10:30AM-12:30PM
Abstract Number: 2547
Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.
10:30AM-12:30PM
Abstract Number: 2271
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
10:30AM-12:30PM
Abstract Number: 1895
Assessing the Validity of Self-Reported Medication Data Through Metabolite Analysis: Data from the Osteoarthritis Initiative
10:30AM-12:30PM
Abstract Number: 2262
Assessment of small airway disease in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 2252
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
10:30AM-12:30PM
Abstract Number: 2366
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
10:30AM-12:30PM
Abstract Number: 2079
Association Between Symptomatic Knee Osteoarthritis and Health-Related Quality of Life in Individuals with Type 2 Diabetes: A Cross-Sectional Study
10:30AM-12:30PM
Abstract Number: 2093
Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-Matched Retrospective Cohort Analysis
10:30AM-12:30PM
Abstract Number: 2254
Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study
10:30AM-12:30PM
Abstract Number: 2325
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2286
Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
10:30AM-12:30PM
Abstract Number: 2092
Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study
10:30AM-12:30PM
Abstract Number: 1925
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2401
Associations between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-Protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2414
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
10:30AM-12:30PM
Abstract Number: 2059
Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)
10:30AM-12:30PM
Abstract Number: 2492
Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
10:30AM-12:30PM
Abstract Number: 2295
Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
10:30AM-12:30PM
Abstract Number: 2382
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
10:30AM-12:30PM
Abstract Number: 2471
Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
10:30AM-12:30PM
Abstract Number: 2172
Automating the Curation and Summarization of Rheumatology Fellowship Applications using Generative AI Agents and Transformer Models
10:30AM-12:30PM
Abstract Number: 2505
Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 2213
Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
10:30AM-10:45AM
Abstract Number: 1754
B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
10:30AM-12:30PM
Abstract Number: 2346
Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
10:30AM-12:30PM
Abstract Number: 1863
Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis
10:30AM-12:30PM
Abstract Number: 2017
Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
10:30AM-12:30PM
Abstract Number: 1975
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
10:30AM-12:30PM
Abstract Number: 2028
Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
10:30AM-12:30PM
Abstract Number: 2535
Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
10:30AM-12:30PM
Abstract Number: 2453
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
10:30AM-12:30PM
Abstract Number: 2439
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
10:30AM-12:30PM
Abstract Number: 2513
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
10:30AM-12:30PM
Abstract Number: 2358
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 2374
Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
10:30AM-12:30PM
Abstract Number: 2341
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 2347
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
10:30AM-12:30PM
Abstract Number: 2345
Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
10:30AM-12:30PM
Abstract Number: 2152
Blau Syndrome: features beyond the classic triad and proposal for clinical criteria
10:30AM-12:30PM
Abstract Number: 2476
Blinatumomab in rapid progressive systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1997
Bone health in patients with gout using real-world U.S. data
10:30AM-12:30PM
Abstract Number: 2431
Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2244
Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
10:30AM-12:30PM
Abstract Number: 1840
Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
10:30AM-12:30PM
Abstract Number: 1770
Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients
10:30AM-12:30PM
Abstract Number: 1982
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
10:30AM-12:30PM
Abstract Number: 2169
Bridging the Gap: A National Needs Assessment of Rheumatology Fellowship Training in Adolescent and Young Adult Care
10:30AM-12:30PM
Abstract Number: 2156
Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)
10:30AM-12:30PM
Abstract Number: 2183
Bridging the Musculoskeletal Ultrasound Training Gap: Analysis of Confidence, Competency, and Clinical Readiness
10:30AM-12:30PM
Abstract Number: 2530
Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 2528
Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 2437
Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
10:30AM-12:30PM
Abstract Number: 1930
Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
10:30AM-12:30PM
Abstract Number: 2021
Can Colchicine Be a Therapeutic Option for Patients with Ankylosing Spondylitis?
10:30AM-12:30PM
Abstract Number: 2000
Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
10:30AM-12:30PM
Abstract Number: 1900
Capturing Patient Cohorts: A Temporal Arteritis Classifier
10:30AM-12:30PM
Abstract Number: 2487
Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink
10:30AM-12:30PM
Abstract Number: 2284
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
10:30AM-12:30PM
Abstract Number: 2317
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
10:30AM-12:30PM
Abstract Number: 1828
CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
10:30AM-12:30PM
Abstract Number: 2465
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
10:30AM-12:30PM
Abstract Number: 2073
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
10:30AM-12:30PM
Abstract Number: 1852
Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
10:30AM-12:30PM
Abstract Number: 1897
Changes in SLE Mortality During and After the COVID-19 Pandemic
10:30AM-12:30PM
Abstract Number: 2210
Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2280
Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2004
Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
10:30AM-12:30PM
Abstract Number: 2029
Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 2001
Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
10:30AM-12:30PM
Abstract Number: 2070
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
10:30AM-12:30PM
Abstract Number: 1999
Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
10:30AM-12:30PM
Abstract Number: 2482
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
10:30AM-12:30PM
Abstract Number: 1911
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
10:30AM-12:30PM
Abstract Number: 1917
Characterizing the Frequency and Timing of Changes in Patient-Reported Social Risk Factors among Rheumatology Outpatients
10:30AM-12:30PM
Abstract Number: 2354
ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2127
Chronic Non-Bacterial Osteomyelitis of the Petrous Bone: A Case Series
10:30AM-12:30PM
Abstract Number: LB17
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
10:30AM-12:30PM
Abstract Number: 1774
Citrullinated and Malondialdehyde-Acetaldehyde Co-Modified Fibrinogen Activates Macrophages and Induces Pro-Fibrotic shift in Coronary Endothelium Phenotype
10:30AM-12:30PM
Abstract Number: 1779
Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
10:30AM-12:30PM
Abstract Number: 2349
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
10:30AM-12:30PM
Abstract Number: 1802
Clearance Kinetics and Cartilage Retention of MM-II, a Dispersion of Large Empty Liposomes, in Rat Knees
10:30AM-12:30PM
Abstract Number: 1908
Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis
10:30AM-12:30PM
Abstract Number: 2250
Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?
10:30AM-12:30PM
Abstract Number: 2423
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
10:30AM-12:30PM
Abstract Number: 2057
Clinical Associations of Anti-Ro52 Antibodies in Idiopathic Inflammatory Myopathies: A Scoping Review
10:30AM-12:30PM
Abstract Number: 2258
Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 2051
Clinical Burden of Illness Among Patients with Immunoglobulin-G4-Related Disease in the United States
10:30AM-12:30PM
Abstract Number: 2166
Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop
10:30AM-12:30PM
Abstract Number: 2356
Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
10:30AM-12:30PM
Abstract Number: 2026
Clinical Features and Treatment Outcomes in Aseptic Abscess Syndrome: A Systematic Review of 104 Cases
10:30AM-12:30PM
Abstract Number: 2404
Clinical features of Elderly-onset Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2015
Clinical features of IgG4-related disease – a single centre experience
10:30AM-10:45AM
Abstract Number: 1766
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
10:30AM-12:30PM
Abstract Number: 2522
Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
10:30AM-12:30PM
Abstract Number: 2022
Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience
10:30AM-12:30PM
Abstract Number: 1910
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
10:30AM-12:30PM
Abstract Number: 1961
Clinical Utility and Patient Experience of Ultrasound-Guided Synovial Biopsy in Refractory Arthritis: A Case Series from a Secondary Care Center
10:30AM-12:30PM
Abstract Number: 2297
Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
10:30AM-12:30PM
Abstract Number: 2293
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 2422
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2302
Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
10:30AM-12:30PM
Abstract Number: 1991
Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
10:30AM-12:30PM
Abstract Number: 2359
Combination Of ­TNF Inhibitors And NSAIDs Versus ­TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2272
Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
10:30AM-12:30PM
Abstract Number: 2294
Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
10:30AM-12:30PM
Abstract Number: 2109
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
10:30AM-12:30PM
Abstract Number: 2370
Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
10:30AM-12:30PM
Abstract Number: 2460
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
10:30AM-12:30PM
Abstract Number: 2538
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
10:30AM-12:30PM
Abstract Number: 2068
Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
10:30AM-12:30PM
Abstract Number: 2496
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
10:30AM-12:30PM
Abstract Number: 2263
Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
10:30AM-12:30PM
Abstract Number: 2514
Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
10:30AM-12:30PM
Abstract Number: 1970
Comparison of Optical Imaging with Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
10:30AM-12:30PM
Abstract Number: 2033
Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 2467
Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1862
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers
10:30AM-12:30PM
Abstract Number: 2499
Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness
10:30AM-12:30PM
Abstract Number: 2069
Concordance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies on subsequent myositis panel testing.
10:30AM-12:30PM
Abstract Number: 2136
Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis
10:30AM-12:30PM
Abstract Number: 2102
Construct Validity of the Six-Minute Walk Test in Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2055
Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
10:30AM-12:30PM
Abstract Number: 2208
Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2512
Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
10:30AM-12:30PM
Abstract Number: 2331
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
10:30AM-12:30PM
Abstract Number: 1947
Coronary computed tomography incidental findings in rheumatoid arthritis.
10:30AM-12:30PM
Abstract Number: 2531
Coronary periarteritis in IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 1957
Correlates Between Cardiovascular Risk Scores with Coronary Microvascular Function and Plaque Burden in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2291
Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 2388
Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
10:30AM-12:30PM
Abstract Number: 1772
Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 2330
Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1940
Correlation of Hand and Lymphatic Function Post Exercise Intervention in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1931
COSMOS Prevalence of aTTP in SLE
10:30AM-12:30PM
Abstract Number: 2111
Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
10:30AM-12:30PM
Abstract Number: 2228
COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis
10:30AM-12:30PM
Abstract Number: 2477
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
10:30AM-12:30PM
Abstract Number: 1878
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
10:30AM-12:30PM
Abstract Number: 2409
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
10:30AM-12:30PM
Abstract Number: 1912
Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
10:30AM-12:30PM
Abstract Number: 1820
Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
10:30AM-12:30PM
Abstract Number: 2521
DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
10:30AM-12:30PM
Abstract Number: 2441
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
10:30AM-12:30PM
Abstract Number: 2048
DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.
10:30AM-12:30PM
Abstract Number: 2502
Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
10:30AM-12:30PM
Abstract Number: 1867
Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
10:30AM-12:30PM
Abstract Number: 1877
Demographics and trends of Inflammatory Arthritis-Related Mortality in the United States, 1999–2019
10:30AM-12:30PM
Abstract Number: 2117
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
10:30AM-12:30PM
Abstract Number: 1952
Dermatoscopy Limitation and the Critical Role of Capillaroscopy in Systemic Sclerosis and Raynaud’s Phenomenon among African American Veterans
10:30AM-12:30PM
Abstract Number: 2049
Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics
10:30AM-12:30PM
Abstract Number: 1810
Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 1791
Determining the Effect of CD14 Deficiency on Osteoblastogenesis and Subchondral Bone Remodeling In Mice
10:30AM-12:30PM
Abstract Number: 1967
Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging
10:30AM-12:30PM
Abstract Number: 1888
Developing Machine Learning Algorithm in Electronic Health Record to Accurately Identify Psoriasis Patients
10:30AM-12:30PM
Abstract Number: 2173
Developing Musculoskeletal Ultrasound Clinical Electives: Bridging the Basic Sciences and Clinical Application in Undergraduate Medical Education
10:30AM-12:30PM
Abstract Number: 2186
Developing Rheumatology Specific Anki Electronic Flashcards for Teaching Preclinical Students United States Medical Licensing Examination Board Relevant Topics 
10:30AM-12:30PM
Abstract Number: 2334
Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
10:30AM-12:30PM
Abstract Number: 2332
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
10:30AM-12:30PM
Abstract Number: 2125
Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
10:30AM-12:30PM
Abstract Number: 2550
Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic
10:30AM-12:30PM
Abstract Number: 2114
Development of a Fracture Prediction Model for Patients Aging with HIV
10:30AM-12:30PM
Abstract Number: 2027
Development of a multi-disease panel for autoimmune diseases
10:30AM-12:30PM
Abstract Number: 2469
Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2541
Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
10:30AM-12:30PM
Abstract Number: 1927
Development of the PREVAIL model of care: Optimizing feasibility and acceptability for trial implementation
10:30AM-12:30PM
Abstract Number: 2191
Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course
10:30AM-12:30PM
Abstract Number: 2240
Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study
10:30AM-12:30PM
Abstract Number: 2184
Diagnosing the Deficit: Addressing Gaps in Rheumatology Training for Internal Medicine Residents
10:30AM-12:30PM
Abstract Number: 2255
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
10:30AM-12:30PM
Abstract Number: 2546
Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
10:30AM-12:30PM
Abstract Number: 2544
Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
10:30AM-12:30PM
Abstract Number: LB15
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
10:30AM-12:30PM
Abstract Number: 2428
Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
10:30AM-12:30PM
Abstract Number: 2243
Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
10:30AM-12:30PM
Abstract Number: 2246
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
10:30AM-12:30PM
Abstract Number: 1838
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
10:30AM-12:30PM
Abstract Number: 2268
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
10:30AM-12:30PM
Abstract Number: 1841
Differential metabolomic signatures along lupus nephritis spectrum
10:30AM-12:30PM
Abstract Number: 2403
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
10:30AM-12:30PM
Abstract Number: 2472
Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time
10:30AM-12:30PM
Abstract Number: 2416
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
10:30AM-12:30PM
Abstract Number: 2408
Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population
10:30AM-12:30PM
Abstract Number: 2430
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1844
Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2199
Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
10:30AM-12:30PM
Abstract Number: 2129
Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses
10:30AM-12:30PM
Abstract Number: 1831
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
10:30AM-12:30PM
Abstract Number: 1833
DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 1913
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
10:30AM-12:30PM
Abstract Number: 1983
Documenting Transition: A Review and Intervention to Increase the Receipt of Transition Summary Letters
10:30AM-12:30PM
Abstract Number: 2087
Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
10:30AM-12:30PM
Abstract Number: 1937
Does Combining Standard MRI-Based Scores with Radiographic Trabecular Bone Texture Biomarkers Improve Predictive Performance for Radiographic Knee Osteoarthritis Progression?
10:30AM-12:30PM
Abstract Number: 2392
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
10:30AM-12:30PM
Abstract Number: 2090
Don’t Throw Out X-Rays! Radiographic Osteoarthritis Severity is Prognostic for Onset of Frequent Knee Pain
10:30AM-12:30PM
Abstract Number: 2419
Dried Blood Spots for Remote ANA and Autoantibody Screening
10:30AM-12:30PM
Abstract Number: 1848
DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
10:30AM-12:30PM
Abstract Number: 2251
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
10:30AM-12:30PM
Abstract Number: 2432
Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2336
Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry
10:30AM-12:30PM
Abstract Number: 2324
Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data
10:30AM-12:30PM
Abstract Number: 2234
Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2164
East Meets West: A Novel Tofu-Pasta-Cardstock Phantom Model for Teaching Ultrasound-Guided Procedures
10:30AM-12:30PM
Abstract Number: 1929
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
10:30AM-12:30PM
Abstract Number: 2179
Educational online webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) for patients, caregivers and healthcare professionals: six years’ experience
10:30AM-10:45AM
Abstract Number: 1748
Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2498
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
10:30AM-12:30PM
Abstract Number: 2440
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
10:30AM-12:30PM
Abstract Number: 2282
Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
10:30AM-12:30PM
Abstract Number: 2110
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
10:30AM-12:30PM
Abstract Number: 2373
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
10:30AM-12:30PM
Abstract Number: 2016
Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients
10:30AM-12:30PM
Abstract Number: 2205
Effectiveness of Reproductive Health Counseling for Rheumatology Patients
10:30AM-12:30PM
Abstract Number: 2281
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
10:30AM-12:30PM
Abstract Number: 2552
Effects of 360° Virtual Reality Embodiment Videos on Pain in Hand Osteoarthritis: A Within-Subject Pre-Post Study
10:30AM-12:30PM
Abstract Number: 2289
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
10:30AM-12:30PM
Abstract Number: 2050
Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis
10:30AM-12:30PM
Abstract Number: 2348
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
10:30AM-12:30PM
Abstract Number: 2014
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR  < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
10:30AM-12:30PM
Abstract Number: 2013
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
10:30AM-12:30PM
Abstract Number: LB08
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
10:30AM-12:30PM
Abstract Number: 2488
Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
10:30AM-12:30PM
Abstract Number: LB11
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
10:30AM-12:30PM
Abstract Number: 2376
Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
10:30AM-12:30PM
Abstract Number: 2466
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1963
Efficacy of Apremilast in Patients With Psoriatic Arthritis and Pre-existing Dactylitis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
10:30AM-12:30PM
Abstract Number: 2288
Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
10:30AM-12:30PM
Abstract Number: 2353
Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
10:30AM-12:30PM
Abstract Number: 1896
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
10:30AM-12:30PM
Abstract Number: 2248
Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study
10:30AM-12:30PM
Abstract Number: 2147
Elevated fMET and GDF-15 Circulating Levels in Pediatric CNO Patients with Psoriasis Define a Distinct Mitochondrial-Inflammatory Signature
10:30AM-12:30PM
Abstract Number: 2005
Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
10:30AM-12:30PM
Abstract Number: 1866
Elucidating gastric pathology in systemic sclerosis using single-cell RNA sequencing
10:30AM-12:30PM
Abstract Number: 1836
Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2478
Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
10:30AM-12:30PM
Abstract Number: 1851
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
10:30AM-12:30PM
Abstract Number: 1837
Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
10:30AM-12:30PM
Abstract Number: 1948
Enhanced Prediction of Knee Osteoarthritis Progression through Deep Learning-Based Multimodal Data Fusion
10:30AM-12:30PM
Abstract Number: 2562
Enhancing Hand Osteoarthritis Classification with Generative AI: A CycleGAN and EfficientNetB7 Approach
10:30AM-12:30PM
Abstract Number: 2195
Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1969
Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
10:30AM-12:30PM
Abstract Number: 1972
Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 2188
Enhancing Pediatric Rheumatology Education Through Case-Based Learning: Impact on Knowledge, Confidence, and Elective Interest
10:30AM-12:30PM
Abstract Number: 2163
Enhancing Post-Conference Engagement Through Expert Q&A: A Pilot Collaboration Between ACR Convergence & theMednet.org
10:30AM-12:30PM
Abstract Number: 2145
EOS® Imaging System Is a Novel, Rapid, Safe, and Effective Technique To Detect And Assess Calcinosis In JDM
10:30AM-12:30PM
Abstract Number: 2202
Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
10:30AM-12:30PM
Abstract Number: 1901
Epidemiology of Adult-Onset Still’s Disease in South Korea: A Nationwide Study Using Health Insurance Claims Data
10:30AM-12:30PM
Abstract Number: 1818
Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
10:30AM-12:30PM
Abstract Number: LB05
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
10:30AM-12:30PM
Abstract Number: 2555
Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program
10:30AM-12:30PM
Abstract Number: 2085
Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
10:30AM-12:30PM
Abstract Number: 1932
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
10:30AM-12:30PM
Abstract Number: 2041
Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review
10:30AM-12:30PM
Abstract Number: 2158
Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis
10:30AM-12:30PM
Abstract Number: 2003
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
10:30AM-12:30PM
Abstract Number: 2094
Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust
10:30AM-12:30PM
Abstract Number: 1973
Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 2415
Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online
10:30AM-12:30PM
Abstract Number: 1987
Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™
10:30AM-12:30PM
Abstract Number: 2083
Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years
10:30AM-12:30PM
Abstract Number: 2249
Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
10:30AM-12:30PM
Abstract Number: 2296
Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
10:30AM-12:30PM
Abstract Number: 2300
Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
10:30AM-12:30PM
Abstract Number: 2520
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
10:30AM-12:30PM
Abstract Number: 2412
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 2133
Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
10:30AM-12:30PM
Abstract Number: 1871
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
10:30AM-12:30PM
Abstract Number: 2216
Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors
10:30AM-12:30PM
Abstract Number: 2107
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
10:30AM-12:30PM
Abstract Number: 1922
Exploration of patient and clinician perspectives on rehabilitation in contemporary rheumatology care for rheumatoid arthritis: A qualitative study
10:30AM-12:30PM
Abstract Number: 1905
Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States
10:30AM-12:30PM
Abstract Number: 2008
Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
10:30AM-12:30PM
Abstract Number: 2226
Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications
10:30AM-12:30PM
Abstract Number: 2378
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
10:30AM-12:30PM
Abstract Number: 2563
Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
10:30AM-12:30PM
Abstract Number: 2138
Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
10:30AM-12:30PM
Abstract Number: 2380
Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
10:30AM-12:30PM
Abstract Number: 2224
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
10:30AM-12:30PM
Abstract Number: 1875
Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
10:30AM-12:30PM
Abstract Number: 2075
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
10:30AM-12:30PM
Abstract Number: 1919
Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE
10:30AM-12:30PM
Abstract Number: 1850
First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
10:30AM-12:30PM
Abstract Number: 2080
Foot laterality does not modify outcome of knee and/or hip osteoarthritis
10:30AM-12:30PM
Abstract Number: LB10
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
10:30AM-12:30PM
Abstract Number: 2119
Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
10:30AM-12:30PM
Abstract Number: 2534
Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
10:30AM-12:30PM
Abstract Number: 1813
Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
10:30AM-12:30PM
Abstract Number: 2313
From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
10:30AM-12:30PM
Abstract Number: 2096
Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
10:30AM-12:30PM
Abstract Number: 2322
Gender-related Differences in Peripheral and Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2260
Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
10:30AM-12:30PM
Abstract Number: 1823
Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever
10:30AM-12:30PM
Abstract Number: 1891
Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
10:30AM-12:30PM
Abstract Number: 2475
GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry
10:30AM-12:30PM
Abstract Number: 2153
Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience
10:30AM-12:30PM
Abstract Number: 1868
Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition
10:30AM-12:30PM
Abstract Number: 1860
GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
10:30AM-12:30PM
Abstract Number: 1777
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
10:30AM-12:30PM
Abstract Number: 2500
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
10:30AM-12:30PM
Abstract Number: 2180
Helping Hands: Curriculum using Simulators to Teach the Hand Exam and Assessment of Small Joint Swelling in Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 2034
Hidden Burden in Rheumatology: Cross-Sectional Study of Hearing Loss in Systemic Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 2536
High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
10:30AM-12:30PM
Abstract Number: 1981
High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education
10:30AM-12:30PM
Abstract Number: 2491
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
10:30AM-12:30PM
Abstract Number: 2402
High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
10:30AM-12:30PM
Abstract Number: 1872
High-throughput Screening Uncovers Distinct Molecular Signatures Linked with HRCT Patterns in SARD-ILD
10:30AM-12:30PM
Abstract Number: 1996
Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
10:30AM-12:30PM
Abstract Number: 1941
How Calculating Consensus Change Scores Can Go Wrong: Lessons from Multi-reader Imaging Assessments in Axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 1805
Human meniscus histopathological and transcriptomic changes at early and advanced stages of knee osteoarthritis
10:30AM-12:30PM
Abstract Number: 2220
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 2413
Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2214
Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
10:30AM-12:30PM
Abstract Number: 2459
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
10:30AM-12:30PM
Abstract Number: 2444
Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
10:30AM-12:30PM
Abstract Number: 2170
I Know It When I See It! Improving Visual Diagnosis Education in Rheumatology Fellowship Training
10:30AM-12:30PM
Abstract Number: 2399
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
10:30AM-12:30PM
Abstract Number: 2140
Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
10:30AM-12:30PM
Abstract Number: 1985
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
10:30AM-12:30PM
Abstract Number: 2529
IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features
10:30AM-12:30PM
Abstract Number: 2495
IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
10:30AM-12:30PM
Abstract Number: 1962
Imaging findings in patients with enteropathic spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2464
IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
10:30AM-12:30PM
Abstract Number: 1845
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
10:30AM-12:30PM
Abstract Number: 2062
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
10:30AM-12:30PM
Abstract Number: 2410
Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2277
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 2146
Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease
10:30AM-12:30PM
Abstract Number: 2510
Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.
10:30AM-12:30PM
Abstract Number: 2267
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
10:30AM-12:30PM
Abstract Number: 2344
Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
10:30AM-12:30PM
Abstract Number: 2363
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
10:30AM-12:30PM
Abstract Number: 2071
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
10:30AM-12:30PM
Abstract Number: 2257
Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort
10:30AM-12:30PM
Abstract Number: 2394
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
10:30AM-12:30PM
Abstract Number: 2553
Impact of Polypharmacy on Treatment Adherence and Its Effect on The Quality of Life in Patients with Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 2518
Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
10:30AM-12:30PM
Abstract Number: 2326
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2266
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
10:30AM-12:30PM
Abstract Number: 2558
Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions
10:30AM-12:30PM
Abstract Number: 2357
Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
10:30AM-12:30PM
Abstract Number: 1892
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
10:30AM-12:30PM
Abstract Number: 2212
Impact of the 2020 ACR Reproductive Health Guidelines on Treatment Strategies and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
10:30AM-12:30PM
Abstract Number: 2238
Impact of Type 2 Diabetes on Cardiovascular and Renal Outcomes in Rheumatoid Arthritis: Insights from a Large-Scale Multi-Center Analysis
10:30AM-12:30PM
Abstract Number: 2273
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
10:30AM-12:30PM
Abstract Number: 2470
Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1976
Implementing a Change Package for Depression Screening and Appropriate Response for Children with Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 2274
Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
10:30AM-12:30PM
Abstract Number: 2256
Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
10:30AM-12:30PM
Abstract Number: 2393
Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
10:30AM-12:30PM
Abstract Number: 2223
Improving collaboration between rheumatology and OBGYN in the reproductive health care of patients with rheumatic disease
10:30AM-12:30PM
Abstract Number: 1984
Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project
10:30AM-12:30PM
Abstract Number: 2217
Improving Patient Counseling on Medication Safety During Reproductive Years
10:30AM-12:30PM
Abstract Number: 1980
Improving Vaccination Rates in the Rheumatology Clinic
10:30AM-12:30PM
Abstract Number: 2486
In vitro antifibrotic effects of nerandomilast on cell types relevant to intestinal remodeling and fibrosis in systemic sclerosis
10:30AM-12:30PM
Abstract Number: 2420
In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)
10:30AM-12:30PM
Abstract Number: 2099
Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
10:30AM-12:30PM
Abstract Number: 2019
Incidence of Coronavirus Disease 2019 in Participants with IgG4-Related Disease Treated with Inebilizumab in the MITIGATE Study
10:30AM-12:30PM
Abstract Number: 1887
Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
10:30AM-12:30PM
Abstract Number: 1893
Increased Atrial Fibrillation Risk in Rheumatoid Arthritis: Greater in Seropositive Than Seronegative Patients
10:30AM-12:30PM
Abstract Number: 2239
Increased Cardiovascular Morbidity in Patients with Rheumatoid Arthritis and Type 2 Diabetes: A Large-Scale Electronic Health Record Analysis
10:30AM-12:30PM
Abstract Number: 2074
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
10:30AM-12:30PM
Abstract Number: 2329
Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
10:30AM-12:30PM
Abstract Number: 2328
Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis
10:30AM-12:30PM
Abstract Number: 2559
Increasing Clinical Trial Awareness in Sample of Underrepresented Systemic Lupus Erythematosus Patients
10:30AM-12:30PM
Abstract Number: 2020
Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
10:30AM-12:30PM
Abstract Number: 2526
Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
10:30AM-12:30PM
Abstract Number: 2044
Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1879
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
10:30AM-12:30PM
Abstract Number: 1812
Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA
10:30AM-12:30PM
Abstract Number: 2556
Information Needs of Patients with Vasculitis
10:30AM-12:30PM
Abstract Number: 2368
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
10:30AM-12:30PM
Abstract Number: 2148
Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
10:30AM-12:30PM
Abstract Number: 2010
Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
10:30AM-12:30PM
Abstract Number: 1915
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
10:30AM-12:30PM
Abstract Number: 2193
Inpatient Rheumatology Consultations at a Tertiary Academic Medical Center: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1846
Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
10:30AM-12:30PM
Abstract Number: 2551
Integrating Advanced Practice Providers into a Rheumatology Musculoskeletal Ultrasound Clinic: Enhancing Patient Access and Procedural Expertise
10:30AM-12:30PM
Abstract Number: 1834
Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
10:30AM-12:30PM
Abstract Number: 1771
Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2035
Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease
10:30AM-12:30PM
Abstract Number: 2287
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1971
Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?
10:30AM-12:30PM
Abstract Number: 2231
Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)
10:30AM-12:30PM
Abstract Number: 2018
Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1902
Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 2493
Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
10:30AM-12:30PM
Abstract Number: 2483
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
10:30AM-12:30PM
Abstract Number: 2023
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
10:30AM-12:30PM
Abstract Number: 1960
Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment
10:30AM-12:30PM
Abstract Number: 2355
Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
10:30AM-12:30PM
Abstract Number: 2375
Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
10:30AM-12:30PM
Abstract Number: 2036
JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis
10:30AM-12:30PM
Abstract Number: 2339
Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
10:30AM-12:30PM
Abstract Number: 2269
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
10:30AM-12:30PM
Abstract Number: 2427
Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
10:30AM-12:30PM
Abstract Number: 2064
Kinematics Underlying IBM-induced Dysphagia
10:30AM-12:30PM
Abstract Number: 2171
Knowledge of Fertility and Infertility Treatments Among Physicians Treating Women with Rheumatic Diseases: FIT-KS Survey
10:30AM-12:30PM
Abstract Number: 2030
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
10:30AM-12:30PM
Abstract Number: 2134
Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
10:30AM-12:30PM
Abstract Number: 2101
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
10:30AM-12:30PM
Abstract Number: 2309
Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
10:30AM-12:30PM
Abstract Number: 2340
Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
10:30AM-12:30PM
Abstract Number: 1808
Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis
10:30AM-12:30PM
Abstract Number: 2063
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
10:30AM-12:30PM
Abstract Number: 2276
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
10:30AM-12:30PM
Abstract Number: 2362
Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
10:30AM-12:30PM
Abstract Number: 2279
Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
10:30AM-12:30PM
Abstract Number: 2352
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
10:30AM-12:30PM
Abstract Number: 2454
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
10:30AM-12:30PM
Abstract Number: 1958
Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?
10:30AM-12:30PM
Abstract Number: 2447
Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
10:30AM-12:30PM
Abstract Number: LB01
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
10:30AM-12:30PM
Abstract Number: 1920
Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
10:30AM-12:30PM
Abstract Number: 2259
Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
10:30AM-12:30PM
Abstract Number: 2387
Lupus Damage Index Revision – Item Generation and Reduction Phases
10:30AM-12:30PM
Abstract Number: 2455
Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
10:30AM-12:30PM
Abstract Number: 2405
Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2406
Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
10:30AM-12:30PM
Abstract Number: 1953
Machine Learning-Based Classification of Raynaud’s Phenomenon and Autoimmune Diseases in Indeterminate Capillaroscopic Patterns
10:30AM-12:30PM
Abstract Number: 2007
Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
10:30AM-12:30PM
Abstract Number: 2264
Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011
10:30AM-12:30PM
Abstract Number: 2045
Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
10:30AM-12:30PM
Abstract Number: 2031
Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
10:30AM-12:30PM
Abstract Number: 2548
Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit
10:30AM-12:30PM
Abstract Number: 1788
Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
10:30AM-12:30PM
Abstract Number: 1904
Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry
10:30AM-12:30PM
Abstract Number: 2407
Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
10:30AM-12:30PM
Abstract Number: 1782
Mapping The Synovial Innervation Of The Human Knee Joint
10:30AM-12:30PM
Abstract Number: 1809
Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
10:30AM-12:30PM
Abstract Number: 2211
Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States
10:30AM-12:30PM
Abstract Number: 2203
Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
10:30AM-12:30PM
Abstract Number: 2457
Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1801
Matrikine Activation of Synovial Fibroblasts Promotes Monocyte Migration and Stimulates an OA Chondrocyte Phenotype
10:30AM-12:30PM
Abstract Number: 2197
Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation
10:30AM-12:30PM
Abstract Number: 2135
Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
10:30AM-12:30PM
Abstract Number: 2207
Menopause Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: LB16
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
10:30AM-12:30PM
Abstract Number: 2303
Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
10:30AM-12:30PM
Abstract Number: 2002
Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
10:30AM-12:30PM
Abstract Number: 2115
METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
10:30AM-12:30PM
Abstract Number: 2429
mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 2501
Microvascular dysfunction contributes to hand bone deterioration in SSc patients
10:30AM-12:30PM
Abstract Number: 1864
Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 2443
Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1780
Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
10:30AM-12:30PM
Abstract Number: 2351
Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2540
Monocyte-to-High-Density Lipoprotein Cholesterol Ratio as a Clinical Marker of Gastrointestinal Involvement in Behçet Syndrome
10:30AM-12:30PM
Abstract Number: 2113
Mortality rate in patients with hip fracture: is it recommendable to establish fracture units?
10:30AM-12:30PM
Abstract Number: 2516
Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
10:30AM-12:30PM
Abstract Number: 1989
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
10:30AM-10:45AM
Abstract Number: 1736
Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
10:30AM-12:30PM
Abstract Number: 1796
Multi-Tissue Molecular and Histopathological Profiling of Facet Joints and Intervertebral Discs
10:30AM-12:30PM
Abstract Number: 2350
Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2108
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
10:30AM-12:30PM
Abstract Number: 2142
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
10:30AM-12:30PM
Abstract Number: 1784
Multimodal Preclinical Screening Of Glucocorticoid-Induced Disruption Of Bone Remodeling In Rat
10:30AM-12:30PM
Abstract Number: 1829
Multiomic Investigation of Juvenile Idiopathic Arthritis Synovium Reveals Immune Cell Heterogeneity
10:30AM-12:30PM
Abstract Number: 2091
Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
10:30AM-12:30PM
Abstract Number: 1944
Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
10:30AM-12:30PM
Abstract Number: 2473
Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm
10:30AM-12:30PM
Abstract Number: 2229
National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease
10:30AM-12:30PM
Abstract Number: 1889
Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe
10:30AM-12:30PM
Abstract Number: 2222
Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
10:30AM-12:30PM
Abstract Number: 1783
Nerve Growth Factor Causes Sensitization, Nociceptor Sprouting, Synovitis, And Osteophyte Formation In Naïve Murine Joints
10:30AM-12:30PM
Abstract Number: 2278
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
10:30AM-12:30PM
Abstract Number: 2310
Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
10:30AM-12:30PM
Abstract Number: 1874
Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis
10:30AM-12:30PM
Abstract Number: 2078
Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
10:30AM-12:30PM
Abstract Number: 2425
Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
10:30AM-12:30PM
Abstract Number: 1815
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
10:30AM-12:30PM
Abstract Number: 2076
Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
10:30AM-12:30PM
Abstract Number: 1792
OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation
10:30AM-12:30PM
Abstract Number: 1794
OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
10:30AM-12:30PM
Abstract Number: 2458
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
10:30AM-12:30PM
Abstract Number: LB13
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
10:30AM-12:30PM
Abstract Number: 2200
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
10:30AM-12:30PM
Abstract Number: 2311
Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities
10:30AM-12:30PM
Abstract Number: 2178
Online Education Significantly Improved Rheumatologists’ Knowledge of the Diagnosis and Management of Sjögren’s Disease
10:30AM-12:30PM
Abstract Number: 1894
Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis
10:30AM-12:30PM
Abstract Number: 1938
Optimizing Patient Outcomes: The Experience of a Multidisciplinary Rheumatology and Hand Surgery Clinic with Point-of-Care Musculoskeletal Ultrasound Integration
10:30AM-12:30PM
Abstract Number: 2157
Optimizing the Diagnosis and Treatment of Kawasaki Disease-Associated Macrophage Activation Syndrome: A Clinical Cohort and Literature Analysis
10:30AM-10:45AM
Abstract Number: 1730
Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
10:30AM-12:30PM
Abstract Number: 1928
Oral Health in Patients with Rheumatic Diseases: A Pilot Quality Improvement Program
10:30AM-12:30PM
Abstract Number: 2418
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
10:30AM-12:30PM
Abstract Number: 2058
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
10:30AM-12:30PM
Abstract Number: 2104
Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989
10:30AM-12:30PM
Abstract Number: 2065
Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
10:30AM-12:30PM
Abstract Number: 2261
Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
10:30AM-12:30PM
Abstract Number: 1870
Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis
10:30AM-12:30PM
Abstract Number: 1803
Patching of Damaged Meniscus and Cartilage of Osteoarthritic Animals by MM-II, a Dispersion of Empty Large Multilamellar Liposomes
10:30AM-12:30PM
Abstract Number: 2449
Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren’s Syndrome: An Analysis Using Japanese Inpatient Database
10:30AM-12:30PM
Abstract Number: 2561
Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
10:30AM-12:30PM
Abstract Number: 2508
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
10:30AM-12:30PM
Abstract Number: 2539
Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort
10:30AM-12:30PM
Abstract Number: 2384
Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
10:30AM-12:30PM
Abstract Number: 2290
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
10:30AM-12:30PM
Abstract Number: 2067
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
10:30AM-12:30PM
Abstract Number: 2533
Patterns of skin lesion transcriptomics in different forms of vasculitis
10:30AM-12:30PM
Abstract Number: 2103
PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2549
Perceived Dignity in Patients With Rheumatic Disease
10:30AM-12:30PM
Abstract Number: 2161
Perceptions of the Importance of Pediatric Rheumatology Education in Pediatric Residency: A Needs Assessment
10:30AM-12:30PM
Abstract Number: 1914
Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology
10:30AM-12:30PM
Abstract Number: 1964
Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome
10:30AM-12:30PM
Abstract Number: 1950
Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
10:30AM-12:30PM
Abstract Number: 2307
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
10:30AM-12:30PM
Abstract Number: 2327
Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
10:30AM-12:30PM
Abstract Number: 1811
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
10:30AM-12:30PM
Abstract Number: 2082
Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial
10:30AM-12:30PM
Abstract Number: 1994
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
10:30AM-12:30PM
Abstract Number: 1804
Pharmacology of LEVI-04, a novel treatment for OA
10:30AM-12:30PM
Abstract Number: 2484
Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
10:30AM-12:30PM
Abstract Number: 2426
Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2308
Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
10:30AM-12:30PM
Abstract Number: 2189
Physician Practices and Perspectives in the Diagnosis and Management of Fibromyalgia: A US Chart Review Study
10:30AM-12:30PM
Abstract Number: 1990
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
10:30AM-12:30PM
Abstract Number: 2215
Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
10:30AM-12:30PM
Abstract Number: 2525
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
10:30AM-12:30PM
Abstract Number: 2318
Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
10:30AM-12:30PM
Abstract Number: 2462
Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
10:30AM-12:30PM
Abstract Number: 1776
Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
10:30AM-12:30PM
Abstract Number: 2509
Predicting future relapse with proteomics in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 2379
Predicting Type 1 and Type 2 SLE Activity Using the LupusPRO
10:30AM-12:30PM
Abstract Number: 2517
Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 2084
Predictors of Change in Physical Activity Level Among Veterans with Knee Osteoarthritis in a Behaviorally Designed Incentive Program
10:30AM-12:30PM
Abstract Number: 2523
Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
10:30AM-12:30PM
Abstract Number: 2305
Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
10:30AM-12:30PM
Abstract Number: 2456
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
10:30AM-12:30PM
Abstract Number: 2218
Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
10:30AM-12:30PM
Abstract Number: 2209
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
10:30AM-12:30PM
Abstract Number: 2126
Preliminary Results of a Large, Global Registry Characterizing Childhood-Onset Takayasu Arteritis
10:30AM-12:30PM
Abstract Number: 2452
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
10:30AM-12:30PM
Abstract Number: 2436
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
10:30AM-12:30PM
Abstract Number: 2106
Prevalence and Characteristics of Morphometric Vertebral Fractures in the Spanish Population: Data from the OsteoSER Study
10:30AM-12:30PM
Abstract Number: 2306
Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
10:30AM-12:30PM
Abstract Number: 2400
Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
10:30AM-12:30PM
Abstract Number: 2481
Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)
10:30AM-12:30PM
Abstract Number: 2052
Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
10:30AM-12:30PM
Abstract Number: 2485
Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
10:30AM-12:30PM
Abstract Number: 2128
Prevalence of Risks and Complications in a Longitudinal International Cohort of Children with Chronic Nonbacterial Osteomyelitis (CNO)
10:30AM-12:30PM
Abstract Number: 2545
Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
10:30AM-12:30PM
Abstract Number: 2121
Prevention of Bone Mass Loss Associated With Aromatase Inhibitors in Breast Cancer. A Study in Real-World Clinical Practice.
10:30AM-12:30PM
Abstract Number: 2265
Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
10:30AM-12:30PM
Abstract Number: LB14
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
10:30AM-12:30PM
Abstract Number: 2235
Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1798
Proteomic Profiling of Chondrogenic Gene Therapy in Human MSCs Reveals Distinct Regenerative Pathways for Articular Cartilage Repair
10:30AM-12:30PM
Abstract Number: 2066
Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 2560
Quality and Accuracy of TikTok Videos on Axial Spondyloarthritis: A Modified DISCERN Analysis
10:30AM-12:30PM
Abstract Number: 1890
Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
10:30AM-12:30PM
Abstract Number: 1951
Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment
10:30AM-12:30PM
Abstract Number: 1946
Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 2230
Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy
10:30AM-12:30PM
Abstract Number: 2221
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2024
Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study
10:30AM-12:30PM
Abstract Number: 2241
RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
10:30AM-12:30PM
Abstract Number: 2314
Radiographic and Ultrasonographic Assessments of Sesamoid Index in Patients with Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2081
Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening
10:30AM-12:30PM
Abstract Number: 2160
RadRheum: Improving Resident and Medical Student Musculoskeletal Radiology Interpretation Skills Utilizing an Interactive Module
10:30AM-12:30PM
Abstract Number: LB12
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
10:30AM-12:30PM
Abstract Number: 1921
Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
10:30AM-12:30PM
Abstract Number: 1926
Real World  Rate of Efficacy of Adalimumab Biosimilars Following a Mandated Switch in an Academic Medical Center
10:30AM-12:30PM
Abstract Number: 2139
Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
10:30AM-12:30PM
Abstract Number: 2364
Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2299
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
10:30AM-12:30PM
Abstract Number: 2342
Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
10:30AM-12:30PM
Abstract Number: 2367
Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
10:30AM-12:30PM
Abstract Number: 2151
Real-World Experience with IL-1 Blockade in Children with Undifferentiated Systemic Autoinflammatory Diseases (uSAIDs)
10:30AM-12:30PM
Abstract Number: 2554
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
10:30AM-12:30PM
Abstract Number: 2369
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
10:30AM-12:30PM
Abstract Number: 2338
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
10:30AM-12:30PM
Abstract Number: 1924
Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
10:30AM-12:30PM
Abstract Number: 2038
Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
10:30AM-12:30PM
Abstract Number: 2196
Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
10:30AM-12:30PM
Abstract Number: 1773
Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers
10:30AM-12:30PM
Abstract Number: 2319
Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
10:30AM-12:30PM
Abstract Number: 2442
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
10:30AM-12:30PM
Abstract Number: 1998
Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
10:30AM-12:30PM
Abstract Number: 1899
Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
10:30AM-12:30PM
Abstract Number: 1955
Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 1949
Relapsing Polychondritis: Mimicking Asthma while Airways get Damaged
10:30AM-12:30PM
Abstract Number: 2557
Relationship Between Sleep Quality and Psychiatric Symptoms in Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1968
Relationship between ultrasonographic and elastographic findings of the median nerve and disease activity and hand function in patients with rheumatoid arthritis
10:30AM-12:30PM
Abstract Number: 2435
Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
10:30AM-12:30PM
Abstract Number: 2124
Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
10:30AM-12:30PM
Abstract Number: 2479
REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
10:30AM-12:30PM
Abstract Number: 2043
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
10:30AM-12:30PM
Abstract Number: 2381
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2507
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
10:30AM-12:30PM
Abstract Number: 2468
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 2480
Respiratory Muscle Weakness in a Systemic Sclerosis Cohort
10:30AM-12:30PM
Abstract Number: 2098
Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
10:30AM-12:30PM
Abstract Number: 1854
Resting-State Functional Magnetic Resonance Imaging Analysis Revealed Altered Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2072
Results of an Integrated Program for Early Cancer Detection in Idiopathic Inflammatory Myopathies
10:30AM-12:30PM
Abstract Number: 1954
Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation
10:30AM-12:30PM
Abstract Number: 2182
Rheum for Improvement: A Needs Assessment Survey for an Internal Medicine Resident Curriculum
10:30AM-12:30PM
Abstract Number: 2150
Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology
10:30AM-12:30PM
Abstract Number: 2167
Rheum4Games: A Game-Based Rheumatology Board Review for Internal Medicine Residents
10:30AM-12:30PM
Abstract Number: 1880
Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities
10:30AM-12:30PM
Abstract Number: 2149
Rheumatology Transitions of Care: Patient Stability and Follow-Up at a Single Center
10:30AM-12:30PM
Abstract Number: 2232
Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort
10:30AM-12:30PM
Abstract Number: 2343
Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
10:30AM-12:30PM
Abstract Number: 1993
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
10:30AM-12:30PM
Abstract Number: 2118
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
10:30AM-12:30PM
Abstract Number: 2448
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 2524
Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort
10:30AM-12:30PM
Abstract Number: 1857
Role of autoantigen-specific reactivity in the pathogenesis of murine interstitial lung disease model with anti-MDA5 antibody mouse model
10:30AM-12:30PM
Abstract Number: 2116
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
10:30AM-12:30PM
Abstract Number: LB09
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
10:30AM-12:30PM
Abstract Number: 2143
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
10:30AM-10:45AM
Abstract Number: 1742
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
10:30AM-12:30PM
Abstract Number: 2042
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
10:30AM-12:30PM
Abstract Number: 2122
Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
10:30AM-12:30PM
Abstract Number: 2292
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
10:30AM-12:30PM
Abstract Number: 2237
Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis
10:30AM-12:30PM
Abstract Number: 2527
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
10:30AM-12:30PM
Abstract Number: 1939
Salivary Gland Ultrasounds Can Be Read by General Radiologists: A Review Of 4 Years of Reports from an Urban Academic Radiology Department
10:30AM-12:30PM
Abstract Number: 1853
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
10:30AM-12:30PM
Abstract Number: 2123
Sclerostin in Aging Bone and Muscle: A Comparative Study of Osteoporosis, Sarcopenia, and Osteosarcopenia
10:30AM-12:30PM
Abstract Number: 1943
Searching for subclinical synovitis and erosions in seropositive palindromic rheumatism: the added value of the ultrasonographic study of feet
10:30AM-12:30PM
Abstract Number: 1903
Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
10:30AM-12:30PM
Abstract Number: 2361
Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
10:30AM-12:30PM
Abstract Number: 1974
Serial ferritin as a diagnostic surrogate marker in Hemophagocytic Lymphohistiocytosis (HLH), a retrospective single-center study
10:30AM-12:30PM
Abstract Number: 1825
Serum proteomic and single cell RNA sequencing analysis reveals macrophage activation syndrome physiology and widespread complement dysregulation are associated with severe dengue infection in a pediatric cohort
10:30AM-12:30PM
Abstract Number: 1835
Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis
10:30AM-12:30PM
Abstract Number: 1797
SEV-101 Exosomes Isolated from Induced Pluripotent Stem Cell – Derived Hyaline Cartilage Tissue – Characterization of Immunomodulatory and Chondro-proliferative Effects In Vitro
10:30AM-12:30PM
Abstract Number: 1786
SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2543
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
10:30AM-12:30PM
Abstract Number: 1806
Sex differences in knee joint microbial DNA of C57BL/6 mice and the effect of cross-sex microbiome transplantation
10:30AM-12:30PM
Abstract Number: 1793
Sex-associated changes to synovial macrophages in the aging joint
10:30AM-12:30PM
Abstract Number: 1935
Sex-associated disparities in industry payments to US authors in high-impact rheumatology journals correlate with author impact
10:30AM-12:30PM
Abstract Number: 1885
Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study
10:30AM-12:30PM
Abstract Number: 1817
Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
10:30AM-12:30PM
Abstract Number: 2316
Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
10:30AM-12:30PM
Abstract Number: 2438
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
10:30AM-12:30PM
Abstract Number: 1865
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
10:30AM-12:30PM
Abstract Number: 2323
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
10:30AM-12:30PM
Abstract Number: 1945
Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
10:30AM-12:30PM
Abstract Number: 1881
Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States
10:30AM-12:30PM
Abstract Number: 1826
Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
10:30AM-12:30PM
Abstract Number: 1830
Single-Cell and Spatial Profiling Reveal Proinflammatory and Profibrotic Fibroblast-Macrophage Niches in Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1816
Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
10:30AM-12:30PM
Abstract Number: 2175
Skin Manifestations of Rheumatic Diseases: Educating Providers to Improve Diagnostic Skills
10:30AM-12:30PM
Abstract Number: 2390
SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight
10:30AM-12:30PM
Abstract Number: 2320
Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
10:30AM-12:30PM
Abstract Number: 1855
Small Bowel Microbial Dysbiosis and Impaired Intestinal Absorptive Function in Systemic Sclerosis- A Single Center Prospective Study
10:30AM-12:30PM
Abstract Number: 1842
Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
10:30AM-12:30PM
Abstract Number: 2198
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
10:30AM-12:30PM
Abstract Number: 2312
Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
10:30AM-12:30PM
Abstract Number: 1785
Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy
10:30AM-12:30PM
Abstract Number: 2450
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
10:30AM-12:30PM
Abstract Number: 1789
Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
10:30AM-12:30PM
Abstract Number: 1787
Spatial and Quantitative Semiautomated Image Analysis of Synovial Biopsies Studied Using a Novel High-Plex Immunofluorescence Platform
10:30AM-12:30PM
Abstract Number: 2233
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
10:30AM-12:30PM
Abstract Number: 1856
Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
10:30AM-12:30PM
Abstract Number: 1819
Spatial Transcriptomic Profiling Reveals Interferon Activation and CD8⁺ T Cell Dominance in Systemic Juvenile Idiopathic Arthritis-Macrophage Activation Syndrome Liver Inflammation
10:30AM-12:30PM
Abstract Number: 1847
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
10:30AM-12:30PM
Abstract Number: 1933
Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey
10:30AM-12:30PM
Abstract Number: 1781
Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
10:30AM-12:30PM
Abstract Number: 2434
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 2025
Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
10:30AM-12:30PM
Abstract Number: 2377
Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2077
Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
10:30AM-12:30PM
Abstract Number: 2040
Steroid Psychosis and Neuropsychiatric Symptoms induced by Corticosteroid Injection in Rheumatology Patients
10:30AM-12:30PM
Abstract Number: 2006
Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
10:30AM-12:30PM
Abstract Number: 2105
Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study
10:30AM-12:30PM
Abstract Number: 1775
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
10:30AM-12:30PM
Abstract Number: 2190
Successful Implementation of an Innovative Rheumatology Curriculum for Internal Medicine Residents: Fellow-Initiated Rheumatology EDUcation Project (FIRED UP)
10:30AM-12:30PM
Abstract Number: 2192
Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout
10:30AM-12:30PM
Abstract Number: 2365
Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
10:30AM-12:30PM
Abstract Number: 2285
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
10:30AM-12:30PM
Abstract Number: 2056
Systematic Review: Nutritional Interventions in Muscle Diseases
10:30AM-12:30PM
Abstract Number: 2130
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
10:30AM-12:30PM
Abstract Number: 1790
Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2165
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
10:30AM-10:45AM
Abstract Number: 1760
Targeting the Female-biased Factor VGLL3 in Cutaneous and Systemic Lupus
10:30AM-12:30PM
Abstract Number: 1876
Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
10:30AM-12:30PM
Abstract Number: 2461
Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
10:30AM-12:30PM
Abstract Number: 2159
Teaching Musculoskeletal Ultrasound Improves Knowledge and Confidence in the Knee Exam: A Pilot Session with Internal Medicine Trainees
10:30AM-12:30PM
Abstract Number: 2532
Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
10:30AM-12:30PM
Abstract Number: 1883
Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.
10:30AM-12:30PM
Abstract Number: 1873
TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
10:30AM-12:30PM
Abstract Number: 2335
The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
10:30AM-12:30PM
Abstract Number: 2411
The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
10:30AM-12:30PM
Abstract Number: 2383
The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
10:30AM-12:30PM
Abstract Number: 2144
The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 2515
The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
10:30AM-12:30PM
Abstract Number: 2132
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
10:30AM-12:30PM
Abstract Number: 1822
The Circulating Immune Profile of Systemic JIA Patients with HLA-DRB1*15 alleles, Eosinophilia, and Lung Disease
10:30AM-12:30PM
Abstract Number: 2433
The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
10:30AM-12:30PM
Abstract Number: 1959
The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
10:30AM-12:30PM
Abstract Number: 2185
The Evolving Digital Landscape of Social Media among Rheumatology Professionals: A Global Analysis by the EULAR SoMeR Study Group
10:30AM-12:30PM
Abstract Number: 2225
The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
10:30AM-12:30PM
Abstract Number: 1884
The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
10:30AM-12:30PM
Abstract Number: 1906
The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023
10:30AM-12:30PM
Abstract Number: 2037
The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution
10:30AM-12:30PM
Abstract Number: 2227
The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
10:30AM-12:30PM
Abstract Number: 2385
The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
10:30AM-12:30PM
Abstract Number: 1995
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
10:30AM-12:30PM
Abstract Number: 1800
The Role of Nociceptor-Expressed Piezo2 in Nervous System Immune Cell Infiltration in a Mouse Model of Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2511
The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis
10:30AM-12:30PM
Abstract Number: 1977
The Westergren Sedimentation Rate: To Be or Not to Be! The Westergren Sedimentation Rate is being “Killed” but has not “Died”.
10:30AM-12:30PM
Abstract Number: 2137
Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
10:30AM-12:30PM
Abstract Number: 1886
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
10:30AM-12:30PM
Abstract Number: 1849
Time-course RNA sequencing analysis of longitudinal peripheral blood samples to elucidate the factors determining treatment resistance in systemic lupus erythematosus
10:30AM-12:30PM
Abstract Number: 1832
Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
10:30AM-12:30PM
Abstract Number: 2506
Timing, Management, and Outcomes of Venous Thromboembolic Events in ANCA-Associated Vasculitis: A Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1843
Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
10:30AM-12:30PM
Abstract Number: 1824
Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
10:30AM-12:30PM
Abstract Number: 2039
To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
10:30AM-12:30PM
Abstract Number: 2451
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: LB02
Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial
10:30AM-12:30PM
Abstract Number: 1992
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
10:30AM-12:30PM
Abstract Number: 1778
Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
10:30AM-12:30PM
Abstract Number: 2100
Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort
10:30AM-12:30PM
Abstract Number: 2089
Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
10:30AM-12:30PM
Abstract Number: 2168
Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level
10:30AM-12:30PM
Abstract Number: 2097
Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
10:30AM-12:30PM
Abstract Number: 1821
Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis
10:30AM-12:30PM
Abstract Number: 1839
Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
10:30AM-12:30PM
Abstract Number: 2219
Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: LB18
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 1827
Transcriptomics and Machine Learning Unraveling the Molecular Drivers of PFAPA Flares
10:30AM-12:30PM
Abstract Number: LB03
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
10:30AM-12:30PM
Abstract Number: 2187
Transforming MSUS Access in Mexico: A Comparative Study of National Trends and a Hybrid Training Cohort
10:30AM-12:30PM
Abstract Number: 2131
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
10:30AM-12:30PM
Abstract Number: 1814
Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
10:30AM-12:30PM
Abstract Number: 2360
Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
10:30AM-12:30PM
Abstract Number: 2141
Treatment of Refractory Still’s/Systemic Juvenile Idiopathic Arthritis Lung Disease with the bi-specific IL-1Beta/IL-18 neutralizing antibody MAS825
10:30AM-12:30PM
Abstract Number: 2372
Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
10:30AM-12:30PM
Abstract Number: 2060
Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
10:30AM-12:30PM
Abstract Number: 2236
Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
10:30AM-12:30PM
Abstract Number: 1795
Trends and Disparities in Osteoarthritis-Related Mortality in the United States: A 21-Year Analysis (1999-2020)
10:30AM-12:30PM
Abstract Number: 2047
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
10:30AM-12:30PM
Abstract Number: 2095
Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)
10:30AM-12:30PM
Abstract Number: 1909
Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.
10:30AM-12:30PM
Abstract Number: 2061
Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis
10:30AM-12:30PM
Abstract Number: 1907
Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021
10:30AM-12:30PM
Abstract Number: 1965
Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
10:30AM-12:30PM
Abstract Number: 2321
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
10:30AM-12:30PM
Abstract Number: 2490
Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-Induced Cardiomyopathy
10:30AM-12:30PM
Abstract Number: 1859
Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)”
10:30AM-12:30PM
Abstract Number: 2489
Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
10:30AM-12:30PM
Abstract Number: 2497
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
10:30AM-12:30PM
Abstract Number: 2474
Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
10:30AM-12:30PM
Abstract Number: 2304
Updates in the local treatments in Primary Sjögren’s Syndrome “Efficacy and Safety”
10:30AM-12:30PM
Abstract Number: 2301
Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
10:30AM-12:30PM
Abstract Number: 2446
Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Reports
10:30AM-12:30PM
Abstract Number: 2566
Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
10:30AM-12:30PM
Abstract Number: 2174
Using Natural Language Processing to Identify Character Strengths in Rheumatology Fellowship Candidate Applications: A Feasibility Study
10:30AM-12:30PM
Abstract Number: 1979
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
10:30AM-12:30PM
Abstract Number: 2046
Utilization of the All of Us Research Program to Study the Impact of Genetic Background on Autoinflammatory Diseases
10:30AM-12:30PM
Abstract Number: 1978
Utilizing a Gap to Target Function in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry Dashboard of Quality Measures
10:30AM-12:30PM
Abstract Number: 2194
Utilizing Case-Based Learning to Teach the Teacher and Improve Health Insurance Literacy
10:30AM-12:30PM
Abstract Number: 1799
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
10:30AM-12:30PM
Abstract Number: 2503
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
10:30AM-12:30PM
Abstract Number: 2333
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
10:30AM-12:30PM
Abstract Number: 2032
Validation of systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS 10) in adult patients with Still’s Disease
10:30AM-12:30PM
Abstract Number: 2009
Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
10:30AM-12:30PM
Abstract Number: 2504
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
10:30AM-12:30PM
Abstract Number: 2537
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
10:30AM-12:30PM
Abstract Number: 1882
Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020
10:30AM-12:30PM
Abstract Number: 1918
Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
10:30AM-12:30PM
Abstract Number: 2298
When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
10:30AM-12:30PM
Abstract Number: 2112
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
10:30AM-12:30PM
Abstract Number: 2421
Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
10:30AM-12:30PM
Abstract Number: 2154
Whole-Body MRI Findings in a Cohort of  Children with Chronic Nonbacterial Osteomyelitis
10:30AM-12:30PM
Abstract Number: 2086
WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
10:30AM-12:30PM
Abstract Number: 2253
Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
10:45AM-11:00AM
Abstract Number: 1731
A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
10:45AM-11:00AM
Abstract Number: 1743
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
10:45AM-11:00AM
Abstract Number: 1737
CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
10:45AM-11:00AM
Abstract Number: 1749
External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis
10:45AM-11:00AM
Abstract Number: 1767
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
10:45AM-11:00AM
Abstract Number: 1755
Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
10:45AM-11:00AM
Abstract Number: 1761
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
11:00AM-11:15AM
Abstract Number: 1738
Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes
11:00AM-11:15AM
Abstract Number: 1756
Exosomal Cargo and Surface Markers: Informative Signals in Axial Spondyloarthritis
11:00AM-11:15AM
Abstract Number: 1732
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
11:00AM-11:15AM
Abstract Number: 1744
Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus
11:00AM-11:15AM
Abstract Number: 1768
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
11:00AM-11:15AM
Abstract Number: 1750
Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
11:15AM-11:30AM
Abstract Number: 1739
Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
11:15AM-11:30AM
Abstract Number: 1769
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
11:15AM-11:30AM
Abstract Number: 1751
Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
11:15AM-11:30AM
Abstract Number: 1745
High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
11:15AM-11:30AM
Abstract Number: 1733
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
11:15AM-11:30AM
Abstract Number: 1757
Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset
11:15AM-11:30AM
Abstract Number: 1763
Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses
1:00PM-1:15PM
Abstract Number: 2597
Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups
1:00PM-1:15PM
Abstract Number: 2591
Association Between Changes in Bone Quality Parameters and Inflammatory Ratios in Postmenopausal Women Treated With Romosozumab: A Retrospective Observational Study
1:00PM-1:15PM
Abstract Number: 2573
Impaired Humoral Response to Recombinant Herpes Zoster Vaccine in Rituximab Treated Autoimmune Rheumatic Diseases Patients: A Prospective Controlled Phase 4 Study
1:00PM-1:15PM
Abstract Number: 2579
Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
1:00PM-1:15PM
Abstract Number: 2567
Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study
1:00PM-1:15PM
Abstract Number: 2585
The effect of prophylactic colchicine use on gene expression in gout
1:15PM-1:30PM
Abstract Number: 2568
Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
1:15PM-1:30PM
Abstract Number: 2574
Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
1:15PM-1:30PM
Abstract Number: 2586
Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
1:15PM-1:30PM
Abstract Number: 2580
Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity
1:15PM-1:30PM
Abstract Number: 2598
Keratinocyte-Secreted Leukemia Inhibitory Factor Counteracts Type I IFN-Induced Antigen-Presenting Phenotype in Melanocytes: Utility in Cutaneous Lupus Skin
1:15PM-1:30PM
Abstract Number: 2592
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
1:30PM-1:45PM
Abstract Number: 2581
From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
1:30PM-1:45PM
Abstract Number: 2599
Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
1:30PM-1:45PM
Abstract Number: 2575
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
1:30PM-1:45PM
Abstract Number: 2587
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
1:30PM-1:45PM
Abstract Number: 2569
Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
1:30PM-1:45PM
Abstract Number: 2593
Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
1:45PM-2:00PM
Abstract Number: 2570
Accelerometer-derived ‘weekend warrior’ physical activity, genetic susceptibility, and incident rheumatoid arthritis: a prospective cohort study
1:45PM-2:00PM
Abstract Number: 2594
Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
1:45PM-2:00PM
Abstract Number: 2600
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
1:45PM-2:00PM
Abstract Number: 2582
Inflammatory Cell Death and Impaired Efferocytosis Drive Monocyte and Macrophage Dysfunction in VEXAS Syndrome.
1:45PM-2:00PM
Abstract Number: 2576
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
1:45PM-2:00PM
Abstract Number: 2588
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
2:00PM-2:15PM
Abstract Number: 2583
CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis
2:00PM-2:15PM
Abstract Number: 2601
Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
2:00PM-2:15PM
Abstract Number: 2577
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
2:00PM-2:15PM
Abstract Number: 2595
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
2:00PM-2:15PM
Abstract Number: 2589
Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
2:00PM-2:15PM
Abstract Number: 2571
Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
2:15PM-2:30PM
Abstract Number: 2578
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
2:15PM-2:30PM
Abstract Number: 2602
Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
2:15PM-2:30PM
Abstract Number: 2572
Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
2:15PM-2:30PM
Abstract Number: 2596
Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach
2:15PM-2:30PM
Abstract Number: 2584
Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
2:15PM-2:30PM
Abstract Number: 2590
Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
3:00PM-3:15PM
Abstract Number: 2633
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
3:00PM-3:15PM
Abstract Number: 2621
Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
3:00PM-3:15PM
Abstract Number: 2603
Evaluating the Feasibility, Acceptability, and Behavioral Impact of Brief Action Planning (BAP) Coaching for Physical Activity in Adults with Chronic Knee Symptoms: A Qualitative Study
3:00PM-3:15PM
Abstract Number: 2609
Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
3:00PM-3:15PM
Abstract Number: 2627
Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
3:00PM-3:15PM
Abstract Number: 2615
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
3:15PM-3:30PM
Abstract Number: 2628
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
3:15PM-3:30PM
Abstract Number: 2604
Cross-Sectional Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The Johnston County Osteoarthritis Project
3:15PM-3:30PM
Abstract Number: 2610
Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy
3:15PM-3:30PM
Abstract Number: 2622
Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
3:15PM-3:30PM
Abstract Number: 2616
Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
3:15PM-3:30PM
Abstract Number: 2634
Sex differences in medication discontinuation in axial spondyloarthritis
3:30PM-3:45PM
Abstract Number: 2617
Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration
3:30PM-3:45PM
Abstract Number: 2635
Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort
3:30PM-3:45PM
Abstract Number: 2623
Disease Activity is a Novel Imaging Biomarker Associated with Knee Pain: Data from the Osteoarthritis Initiative
3:30PM-3:45PM
Abstract Number: 2605
Do Patients Recall Their Rheumatic Diagnoses Accurately? A Comparison by Disease Type
3:30PM-3:45PM
Abstract Number: 2611
Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease
3:30PM-3:45PM
Abstract Number: 2629
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
3:45PM-4:00PM
Abstract Number: 2636
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
3:45PM-4:00PM
Abstract Number: 2612
Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
3:45PM-4:00PM
Abstract Number: 2618
Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers
3:45PM-4:00PM
Abstract Number: 2624
Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee
3:45PM-4:00PM
Abstract Number: 2630
The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
3:45PM-4:00PM
Abstract Number: 2606
The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
4:00PM-4:15PM
Abstract Number: 2631
Dapirolizumab Pegol, a Novel CD40L Inhibitor, Showed No Adverse Outcomes in an In Vivo Non-Human Primate Reprotoxicity Study and Displayed Minimal to No Human Placental Transfer in an Ex Vivo Study
4:00PM-4:15PM
Abstract Number: 2625
Early Detection of Knee Osteoarthritis – The Role of a Composite Disease Activity Metric: Data from the Osteoarthritis Initiative
4:00PM-4:15PM
Abstract Number: 2607
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
4:00PM-4:15PM
Abstract Number: 2613
Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
4:00PM-4:15PM
Abstract Number: 2637
Initial Phospholipid Transferase Activity Is Predictive of Five-Year Sacroiliac Radiographic Progression in Axial Spondyloarthritis: Findings From the DESIR Cohort
4:00PM-4:15PM
Abstract Number: 2619
What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
4:15PM-4:30PM
Abstract Number: 2638
ASembleNet: A Hybrid AI Model for MRI-Based Classification of Ankylosing Spondylitis
4:15PM-4:30PM
Abstract Number: 2614
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
4:15PM-4:30PM
Abstract Number: 2626
Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
4:15PM-4:30PM
Abstract Number: 2632
Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies
4:15PM-4:30PM
Abstract Number: 2608
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
4:15PM-4:30PM
Abstract Number: 2620
Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System
8:00AM-8:15AM
Abstract Number: LB19
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
8:15AM-8:30AM
Abstract Number: LB20
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
8:30AM-8:45AM
Abstract Number: LB21
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
8:45AM-9:00AM
Abstract Number: LB22
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
9:00AM-9:15AM
Abstract Number: LB23
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
9:15AM-9:30AM
Abstract Number: LB24
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)
9:30AM-9:45AM
Abstract Number: 2645
Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
9:30AM-9:45AM
Abstract Number: 2651
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
9:30AM-9:45AM
Abstract Number: 2639
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
9:45AM-10:00AM
Abstract Number: 2652
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
9:45AM-10:00AM
Abstract Number: 2646
DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
9:45AM-10:00AM
Abstract Number: 2640
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
10:00AM-10:15AM
Abstract Number: 2641
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
10:00AM-10:15AM
Abstract Number: 2653
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
10:00AM-10:15AM
Abstract Number: 2647
Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
10:15AM-10:30AM
Abstract Number: 2654
Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
10:15AM-10:30AM
Abstract Number: 2642
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
10:15AM-10:30AM
Abstract Number: 2648
Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares
10:30AM-10:45AM
Abstract Number: 2655
Fetal and maternal outcomes in systemic sclerosis and very early diagnosis of systemic sclerosis pregnancies, a national prospective study
10:30AM-10:45AM
Abstract Number: 2643
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
10:30AM-10:45AM
Abstract Number: 2649
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
10:45AM-11:00AM
Abstract Number: 2650
LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
10:45AM-11:00AM
Abstract Number: 2656
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
10:45AM-11:00AM
Abstract Number: 2644
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
11:30AM-11:45AM
Abstract Number: 2693
CAR T-cell Therapy in SLE: A Systematic Review
11:30AM-11:45AM
Abstract Number: 2699
Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
11:30AM-11:45AM
Abstract Number: 2681
Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
11:30AM-11:45AM
Abstract Number: 2687
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
11:30AM-11:45AM
Abstract Number: 2657
Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort
11:30AM-11:45AM
Abstract Number: 2663
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
11:30AM-11:45AM
Abstract Number: 2675
RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis
11:30AM-11:45AM
Abstract Number: 2669
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
11:45AM-12:00PM
Abstract Number: 2694
Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
11:45AM-12:00PM
Abstract Number: 2682
Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
11:45AM-12:00PM
Abstract Number: 2700
Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
11:45AM-12:00PM
Abstract Number: 2664
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
11:45AM-12:00PM
Abstract Number: 2670
Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
11:45AM-12:00PM
Abstract Number: 2658
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
11:45AM-12:00PM
Abstract Number: 2688
Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
11:45AM-12:00PM
Abstract Number: 2676
Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
12:00PM-12:15PM
Abstract Number: 2683
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
12:00PM-12:15PM
Abstract Number: 2695
B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
12:00PM-12:15PM
Abstract Number: 2689
Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
12:00PM-12:15PM
Abstract Number: 2671
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
12:00PM-12:15PM
Abstract Number: 2701
Ophthalmic Manifestations of Relapsing Polychondritis
12:00PM-12:15PM
Abstract Number: 2665
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
12:00PM-12:15PM
Abstract Number: 2677
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
12:00PM-12:15PM
Abstract Number: 2659
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
12:15PM-12:30PM
Abstract Number: 2696
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
12:15PM-12:30PM
Abstract Number: 2702
Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
12:15PM-12:30PM
Abstract Number: 2690
Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
12:15PM-12:30PM
Abstract Number: 2684
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
12:15PM-12:30PM
Abstract Number: 2666
Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
12:15PM-12:30PM
Abstract Number: 2672
Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
12:15PM-12:30PM
Abstract Number: 2678
The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
12:15PM-12:30PM
Abstract Number: 2660
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
12:30PM-12:45PM
Abstract Number: 2697
A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis
12:30PM-12:45PM
Abstract Number: 2667
Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models
12:30PM-12:45PM
Abstract Number: 2685
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
12:30PM-12:45PM
Abstract Number: 2679
Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort
12:30PM-12:45PM
Abstract Number: 2661
Heterogeneity of RA-ILD by Longitudinal Forced Vital Capacity Measurements Is Associated with Survival and Respiratory Hospitalization
12:30PM-12:45PM
Abstract Number: 2703
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
12:30PM-12:45PM
Abstract Number: 2673
Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
12:30PM-12:45PM
Abstract Number: 2691
Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
12:45PM-1:00PM
Abstract Number: 2668
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
12:45PM-1:00PM
Abstract Number: 2698
Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
12:45PM-1:00PM
Abstract Number: 2704
Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
12:45PM-1:00PM
Abstract Number: 2680
High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
12:45PM-1:00PM
Abstract Number: 2686
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
12:45PM-1:00PM
Abstract Number: 2692
Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
12:45PM-1:00PM
Abstract Number: 2674
Pulmonary ultrasound findings and their relationship with clinical characteristics and myopathy antibodies in a cohort of patients with myositis
12:45PM-1:00PM
Abstract Number: 2662
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease

« View all sessions from this meeting